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Summary 
Excess of energy intake combined with reduced physical activity leads to accumulation and 
expansion of adipose tissue. Imbalance between adipose tissue expansion and oxygenation 
during a high fat diet results in adipocytes stress and defects to store excessive energy. Pro-
inflammatory mediators produced by stressed adipocytes and infiltrated classically activated 
macrophages eventually trigger low grade and chronic inflammation. Several studies 
highlighted that obesity-induced chronic inflammation is a critical factor that triggers insulin 
resistance and alters the cellular composition within the adipose tissue.  
Given that parasitic helminths are well known immunoregulators of host immune responses 
which induce a suppressive, regulatory immune response via the induction of regulatory T 
cells, AAM, anti-inflammatory cytokines, and induce a type 2 immune response, the aim of 
this thesis was to investigate whether the tissue–invasive rodent filarial nematode 
Litomosoides sigmodontis (L.s.) mediates protection against insulin-resistance in diet-
induced obese (DIO) mice by counter-regulating inflammatory immune responses during a 
high fat diet.  
In order to study whether L.s. infection has a beneficial impact on high fat diet-induced 
insulin resistance, 6 week old male BALB/c mice were fed with a high fat diet and a 
subgroup was infected 2-4 weeks later with L.s.. Following 8-10 weeks on high fat diet, mice 
were evaluated for glucose tolerance and immune responses. In separate experiments, daily 
injections of LsAg for 2 weeks were performed in male DIO C57BL/6 mice after 7-12 weeks 
of high fat diet feeding. DIO mice were evaluated for glucose tolerance and immunological 
studies afterwards. 
This thesis demonstrates that both L.s. infection and LsAg administration improved glucose 
tolerance in DIO mice. This improvement was associated with increased eosinophil and AAM 
frequencies within the stromal vascular fraction of the epididymal adipose tissue (EAT) 
during L.s. infection and LsAg administration. Absence of eosinophils abrogated the 
beneficial impact of L.s. infection as was shown with eosinophil deficient dblGATA mice, 
suggesting that improved glucose tolerance by L.s. infection was dependent on eosinophils. 
 
 
2 
 
Further analysis showed reduced total numbers of B cells, but an increased frequency of the 
B1 subset in the adipose tissue of L.s.-infected DIO mice compared to uninfected DIO 
controls. Accordingly, pathogenic IgG2a/b levels were lower in L.s.-infected animals 
compared to uninfected DIO controls. qPCR array analysis of EAT further revealed an 
induction of genes related to insulin signaling, cell migration, suppressive immune responses 
as well as a reduced expression of genes related to adipogenesis in L.s.-infected DIO mice. 
Our in vitro experiments using the 3T3-L1 pre-adipose cell line confirmed that LsAg 
treatment suppressed the differentiation to mature adipocytes.  
Multiple gene expression analysis of EAT from DIO mice that obtained LsAg administrations 
further revealed an induction of type 2 immune responses, as well as an upregulated 
expression of genes-related to insulin signalling and genes-related to fatty acid uptake in 
LsAg-treated DIO mice. Two weeks of daily LsAg administration in DIO mice further 
improved body temperature tolerance under cold exposure, which was accompanied by an 
increased expression of Ucp1 in EAT, suggesting that LsAg administration promotes 
browning of white adipose tissue and increased energy expenditure. 
In conclusion, this thesis demonstrates that both L.s. infection and LsAg administration 
reduces diet-induced EAT inflammation, improves insulin signaling, and glucose tolerance. 
The findings of this thesis suggest that helminth-derived products may offer a new strategy 
to ameliorate diet-induced insulin resistance. 
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1. Introduction 
1.1 Diabetes – a major health problem in the world 
Diabetes is a tremendous health problem throughout the world. It is a chronic 
metabolic disease that is characterized by high blood glucose levels which are either 
due to the insufficient insulin production by the pancreas or an impaired insulin 
sensitivity [1]. Generally, diabetes is divided into 2 main types, type 1 diabetes (T1D) 
and type 2 diabetes (T2D). 
Diabetes leads to a risk of several other diseases as a result of the macro- and 
microvascular blood vessel damage and affects many organs such as eyes, brain, 
heart, and kidney [2]. Recent studies further reported that diabetes is also associated 
with an increased risk to develop cancer and dementia [3,4]. Insulin therapy reduces 
the risk of these co-morbidities, but becomes more difficult over time and represents 
a major cost factor.  
According to the International Diabetes Federation (IDF), around 387 million people 
in the world suffered from diabetes in 2014 [5]. Diabetes incidence is still increasing 
both in developed and developing countries worldwide (Fig.1). Without collective 
effort, the number of diabetes patients was predicted to increase by more than 55% 
by 2035 to a total of 592 million patients [2]. In 2014, it was reported that 4.9 million 
people died due to diabetes and US $612 billion were spent for diabetes healthcare 
[5].    
 
 
 Introduction 
4 
 
 
Figure 1. Worldwide number of people (20-79 years) suffering from diabetes in 2014.  
Source: IDF Diabetes Atlas 6th edn. 2014 update [5]. 
1.1.1 Type 2 Diabetes 
In most populations, 90% of all diabetes cases are due to T2D [6]. In this type of 
diabetes, insulin production by the pancreatic beta (ß)-islet cells still occurs but is 
insufficient to compensate the insulin resistance of insulin target tissues and results 
therefore in increased blood glucose levels. In other words, T2D can be defined as a 
metabolic disorder that is characterized by high blood glucose levels in the context 
of insulin-resistance and relative insulin deficiency. Insulin resistance is associated 
with obesity, ageing and physical inactivity [1]. In order to compensate the insulin 
resistance pancreatic islets initially enhance their cell mass and insulin secretion [7] 
and T2D develops when the functional expansion of β-islet cells fail to compensate 
for the degree of insulin resistance [7]. Exogenous insulin is required to control blood 
glucose levels if diet control or anti-hyperglycemic medication cannot maintain the 
normal blood glucose levels anymore. More than 50% of T2D patients require insulin 
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therapy due to an additional dysfunction of β-islet cells 10 years after the onset of 
insulin resistance [8,9].  
1.1.2 Insulin and its role in energy metabolism 
Glucose is an essential energy source for the body, especially for the brain. In order 
to be converted into energy, glucose has to be taken up by cells. Insulin is a peptide 
hormone produced and secreted by β-cells in the islets of the pancreas. Binding of 
insulin with its receptor allows glucose to enter the cells. Increased glucose levels in 
the blood stimulate the release of insulin from the ß-cells in pancreas [10].  
Excess of glucose can be stored as glycogen in the liver. Between meals, when no 
glucose is supplied from the outside, these stores can be used to provide glucose for 
the brain. Skeletal muscle can also store large quantities of glucose in the form of 
glycogen when glucose is abundant. In contrast to the liver, it cannot release glucose 
to the blood to provide it as energy source for the brain [11].    
Once Insulin binds to its receptor at the extra-cellular binding domain, the receptor 
will be activated, and induce tyrosine kinase activity in the intracellular part to 
phosphorylate tyrosine residues not only residing in the receptor itself but also in the 
insulin receptor substrate (IRS) molecules. Phosphorylated IRS binds and activates 
other proteins. In muscle and adipose tissue, the insulin cascade leads to the 
translocation of glucose transporter (GLUT)-4 from the intracellular compartment to 
the cell membrane [12]. Since GLUT-4 has a high affinity for glucose, it facilitates 
glucose transport into the cells effectively. In general, increased GLUT-4 expression 
on the cell membrane of muscle and adipose cells parallels the increased capacity of 
these cells to take up glucose. 
In addition, receptor activation by insulin also activates the mitogen-activated 
protein kinases (MAPK) pathway [13]. Activated MAPK enters the cell nucleus, 
activates transcription factors of specific genes that are related to anabolic activity 
and activates the protein synthesis which results in an increased amino acid entry 
into the cells. Thus, insulin also reduces amino acid levels in the plasma. 
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Unlike in the adipose and muscle cells, the glucose transport into liver cells is 
facilitated by GLUT-2, but the presence of GLUT-2 is not influenced by insulin. 
Nevertheless, the fate of glucose in liver cells is regulated by insulin. Insulin activates 
glucokinase, an enzyme which phosphorylates incoming glucose to be incorporated 
into glycogen. In contrast, catabolic activity like glycogenolysis and gluconeogenesis 
is inhibited by insulin [14]. 
In addition, insulin enhances liver glycolysis and promotes lipogenesis, the formation 
of fat in the liver, by stimulating the synthesis of fatty acids from glucose. These fatty 
acids are then incorporated into triglyceride (TG) after esterification with glycerol 
and stored as lipid droplets or are exported to the blood as very low density 
lipoproteins (VLDL) [15]. 
1.1.3 Insulin action in adipocytes 
The main function of adipocytes is to store excess fatty acids in the form of TG. If 
required, adipocytes can release fatty acids as energy substrate for other tissues like 
skeletal muscle. The majority of the fatty acids reach the adipose tissue as TG in two 
types of lipoproteins, chylomicrons from the intestine and VLDL from the liver. 
Adipocytes secrete an enzyme, lipoprotein lipase (LPL), which functions on the 
luminal surface of the capillary endothelial cells to hydrolyze TG from lipoproteins 
into fatty acids and glycerol. After hydrolization by LPL, the liberated fatty acids are 
taken up into adipocytes. Insulin can enhance the supply of fatty acids to adipocytes 
by inducing the expression of LPL in adipocytes. 
In the fed state, insulin stimulates the translocation of GLUT-4 to the plasma 
membrane and activates glycerolphosphate acyl transferase for the TG synthesis in 
adipocytes. In addition, insulin also inhibits lipolysis that releases fatty acids from TG 
by activating phosphodiesterase (PDE) to reduce cellular cyclic Adenosine 
Monophosphate (cAMP) levels [16]. In the insulin resistant state, lipolysis is 
increased and leads to fatty acid release into the circulation. 
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1.1.4 Obesity, inflammation and insulin resistance  
Excessive food intake in combination with reduced physical activity initiates the 
imbalance between energy input and energy expenditure [17]. The extra energy will 
be stored as reserved energy source in the form of glycogen in liver and muscle as 
well as lipid in adipose tissue [17]. As professional storage, adipose tissue has an 
almost unlimited capacity to store excessive energy. The diameter of a normal 
adipocyte is in the range of 50µm. Lipid droplet formation in the adipocytes 
continuously increase the storage of excessive energy and leads to lipid 
accumulation and adipocyte enlargement called hypertrophy [18]. In this condition, 
the diameter of adipocytes increases up to 100µm. This eventually expands the body 
fat tissue in whole, especially in subcutaneous and visceral adipose tissue (VAT) and 
results in obesity.  
Obesity is a major risk factor to develop T2D and is associated with low grade chronic 
inflammation. Adipocyte hypertrophy and tissue expansion in obesity leads to an 
impaired oxygenation of cells due to the imbalance between increase of oxygen 
demand and supply by blood innervations [19,20]. Overtime, adipocytes suffer from 
hypoxia and undergo oxidative stress which initiates inflammatory cytokine 
production and apoptosis [19,20]. This leads to the infiltration and accumulation of 
classically activated macrophages (CAM) into the adipose tissue, resulting in low 
grade inflammation and changes in the cellular composition (Fig. 2).  
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Figure 2. Obesity leads to adipocyte apoptosis and macrophage infiltration into adipose tissue. 
Several inflammatory responses including Toll-like receptor (TLR) and inflammasome induction, 
reactive oxygen species (ROS) release, and endoplasmic reticulum (ER) stress lead to pro-
inflammatory cytokine production which impairs insulin signaling in adipose tissue, muscle, liver, and 
kidney, resulting in elevated blood glucose levels. 
Source : Cipolletta D, Kolodin D, Benoist C, Mathis D. Tissular T(regs): a unique population of 
adipose-tissue-resident Foxp3+CD4+ T cells that impacts organismal metabolism. Semin Immunol. 
Elsevier Ltd; 2011;23: 431–7 [21]. 
 
1.1.5 Mechanisms of insulin resistance 
Several cytokines and chemokines, such as monocyte chemotactic protein (MCP)-1, 
the chemokine (C-C motif) ligand (CCL)-2, interleukin (IL)-6, IL-1β, macrophage 
migration inhibitory factor (MIF), and tumor necrosis factor-alpha (TNFα), can be 
released by both stress adipocytes and macrophages [22–24].  
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Elevated levels of pro-inflammatory cytokines as mentioned above was evidenced in 
obesity and is associated with insulin resistance [25]. In addition, C-reactive protein 
(CRP), IL-6, plasminogen activator Inhibitor (PAI-1) and many other inflammatory 
mediators were reported to be increased in the plasma of obese mice [24,26]. TNFα, 
FFA, diacylglyceride (DAG), ceramide, reactive oxygen species (ROS) and hypoxia 
activate intracellular signaling pathways such as IҡBα kinase β (IKKβ) and c-Jun N-
terminal kinase (JNK)-1 in adipose tissue and liver [27] and result in the inhibition of 
IRS-1 [28–30]. Moreover, TNFα leads to insulin resistance via the inhibition of the 
peroxisome proliferator-activated receptor gamma (PPARγ) function [31,32] 
IKKß activation phosphorylates Iҡßα, induces Iҡßα ubiquitination and its degradation 
in the proteosome results in the translocation of nuclear factor kappa B (NFҡß) into 
the nucleus to induce the expression of various genes involved in inflammation and 
other immune responses. IKKß also inhibits insulin signaling through phosphorylation 
of serine residues of IRS-1 in adipocytes [29,33]. JNK activation also inhibits insulin 
signaling by phosphorylation of IRS-1 in response to TNFα [30,34] (Fig. 3). 
Alternatively, insulin signaling is inhibited through the Janus kinase / signal 
transducer and activator of transcription (JAK/STAT) pathway. Tyrosine 
phosphorylation of STAT by JAK kinases induces dimerization and translocation of 
STAT to the nucleus [35] and leads to IRS-1 phosphorylation at Serine (Ser)636 and 
Ser307 [36]. 
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Figure 3. Intracellular mechanisms of inflammatory insulin resistance. Insulin signaling is 
transmitted from the cell surface to cytoplasmatic and nuclear responses via tyrosine 
phosphorylation of insulin receptor substrate (IRS)-1 and -2. Nevertheless, insulin action is inhibited 
through serine phosphorylation of IRS substrates by IKKβ and JNK1, the mediators of stress and 
inflammatory responses. In addition, JNK1 and IKKβ induce the transcriptional activation of 
inflammatory genes, resulting in insulin resistance in an autocrine and paracrine manner in tissues. 
Furthermore, during obesity, influx of free fatty acids (FFA) and glucose also activate JNK1 and IKKβ 
signaling pathways. 
Source: Odegaard JI, Chawla A. Alternative macrophage activation and metabolism. Annu Rev 
Pathol. 2011;6: 275–97 [37]. 
 
As a consequence of insulin signaling inhibition, glucose in the circulation cannot be 
uptaken into the cells and leads to high glucose levels in the blood plasma. 
Furthermore, insulin signaling inhibition impairs anabolic metabolism, and shifts the 
metabolism to catabolic states including breakdown of lipid storage (lipolysis) and 
results in elevated free fatty acids (FFA) in the blood circulation [38]. Subsequently, 
fatty acids from food intake further increases the TG levels in the blood. Given the 
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reduced ability of adipose tissue to store TG during insulin resistance, excessive TG 
are stored ectopically in the liver, leading to fatty liver (hepatosteatosis) [17]. In 
addition, ectopic lipid storage also occurs in muscle tissue [39]. The accumulation of 
lipid intermediates such as DAG in non-adipose tissue results in cellular dysfunction 
and cell death and is termed lipotoxicity. By inducing phosphorylation of IRS at serine 
residues, DAG leads to the inactivation of IRS and triggers lipotoxicity-induced insulin 
resistance [40]. On the other hand, along with increasing levels of inflammatory 
cytokines and chemokines, systemic FFA trigger the inflammation of insulin target 
organs like liver and muscle via Toll-like receptor (TLR)-4 [41–43]. Taken together, 
both inflammatory mediators and hyperlipidemia can trigger insulin resistance. 
1.1.6 Alteration of cellular composition during obesity 
Low grade inflammation during obesity is associated with the alteration of the 
cellular composition in the adipose tissue [21]. Infiltration of immune cells into the 
inter-space of adipocytes within the adipose tissue changes the cellular composition 
within the adipose tissue and leads to the formation of “crown-like structures”. 
Those changes include the loss of eosinophils, alternatively activated macrophages 
(AAM) and regulatory T (Treg) cells and increases accumulation of classically 
activated macrophages (CAM) and B-cells [44–47].  
1.1.6.1 Eosinophils 
Eosinophils are induced by type 2 immune responses and may function as effector 
cells, antigen–presenting cells (APC) [48] and were recently reported to be 
involved in tissue homeostasis, modulation of adaptive immune responses and 
innate immunity to certain microbes [49].  
Eosinophils are well known for their function during helminth infection and allergic 
diseases [48]. Eosinophils are able to produce type 1, type 2 as well as 
immunoregulatory cytokines and are involved in the regulation of type 2 immune 
responses [49]. Furthermore, eosinophils can produce molecules that are 
implemented in protective immune responses against parasitic filarial nematodes 
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as was sown for eosinophil peroxidase (EPO) and major basic protein (MBP) [50–
52].    
Interestingly, recent studies revealed that eosinophils are also involved in the 
metabolic homeostasis and regulation of energy expenditure. Wu et al. reported 
that in adipose tissue, eosinophils are present in low numbers and decline during 
obesity in mice. They also demonstrated that IL-4 producing eosinophils play a role 
in maintaining AAM in visceral adipose tissue and promote glucose tolerance in 
diet-induced obese (DIO) mice [44]. Conversely, the absence of eosinophils impairs 
glucose tolerance in DIO mice [44,53]. In this context they further demonstrated 
that infection with the intestinal nematode Nippostrongylus brasiliensis increased 
eosinophil numbers in the adipose tissue of mice.  
Eosinophils were also linked indirectly to energy expenditure through their role in 
sustaining AAM in adipose tissue by secreting IL-4. Under cold exposure, AAM 
produce catecholamine which can induce the browning of adipose tissue, thus 
increasing energy expenditure [54,55]. A recent study further reported that 
meteorin-like (Metrnl), a new protein which is produced in muscles during exercise 
and adipocytes during cold exposure, has been identified as an inducer of IL-4 
expressing eosinophils in adipose tissue [56]. Hence, eosinophils may have a role to 
ameliorate insulin resistance via suppression of inflammatory immune responses 
and by increasing energy expenditure. 
1.1.6.2 Macrophages 
Macrophages have an important role in immune responses and tissue 
homeostasis. Numerous studies reported that various stimulations activate 
macrophages to release cytokines, chemokines, and metabolic enzymes in distinct 
patterns that ultimately generate the variation of functions seen in inflammatory 
and non-inflammatory settings. In general, CAM promote inflammation and AAM 
suppresses inflammation [57,58]. CAM are characterized by high levels of IL-12, 
inducible nitric oxide synthase (iNOS or NOS2), and major histocompatibility 
complex (MHC) class II expression [57,58]. During obesity, CAM infiltrate into the 
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adipose tissue (49), causing low grade inflammation by production of TNFα and 
other pro-inflammatory cytokines (50). Polarization of CAM are induced by LPS and 
interferon (IFN)γ [59]. 
Unlike CAM, polarization of AAM are induced by IL-4 and IL-13 [57], which can be 
produced by eosinophils and Th2 cells during type 2 immunity [41]. AAM produce 
anti-inflammatory IL-10, arginase, and Resistin-Like Molecule alpha (RELMα) 
[35,60]. In addition, arginase, an enzyme expressed in AAM blocks iNOS activity 
through a variety of mechanisms, including competition for arginine which is 
required for nitric oxide (NO) production [61].  
Thus, AAM are believed to suppress inflammatory responses and promote tissue 
repair [62]. In addition, recent studies demonstrated that IL-4–mediated AAM 
polarization is associated with the activation of transcription factors that are 
involved in the lipid oxidative metabolism including PPARγ and PPARγ coactivator 
1β (PGC-1β) [63]. 
1.1.6.3 Regulatory T-cells  
Tregs are a subset of T lymphocytes that constitute 5–20% of the cluster of 
differentiation (CD)4+ T-cell population [64]. They mediate immune suppression in 
the contexts of autoimmunity, allergy, inflammation, infection, and tumorigenesis 
[65,66]. Tregs regulate other T cell populations and influence innate immune cell 
activity [67–69]. Treg cells are marked by expression of the forkhead–winged-helix 
transcription factor-3 (Foxp3) as well as CD25.  
Based on their origins, Tregs are divided into two main groups: thymus derived 
natural Tregs (nTreg) and inducible Tregs (iTreg). Natural Tregs circulate in the 
blood in the absence of pathogens or tissue damage while inducible Tregs (iTreg) 
have a regulatory function after pathogen or neoplasm exposure. In parasitic 
infection, induction of Tregs is believed as a strategy used by the helminths to 
modulate the host’s immune response, facilitating their long term survival.    
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Tregs are present in the visceral adipose tissue and are associated with improved 
insulin sensitivity. In lean mice, frequency of adipose tissue Tregs is 20-30% of 
CD4+ T-cells, while in obese mice, the frequency of Treg drops by 70% compared to 
lean mice. Induction of Tregs by injecting anti-CD3 specific antibodies to diet-
induced obese (DIO) mice was demonstrated to improve glucose tolerance [64,70]. 
The exact mechanisms by which regulatory CD4+ T cells promote insulin sensitivity 
require further study, but it is suggested to rely on the induction of IL-10–secreting 
AAM [70]. 
1.1.6.4 B-cells   
During high fat (HF) diet-induced obesity, total B cell populations increase in 
visceral adipose tissue and peak by 3–4 weeks after the initiation of HF diet 
[46,71]. B cells consist of distinct subsets including B-1 and B-2 cells. B-1 cells 
dominate in mucosal tissues and pleural/peritoneal cavities while B-2 cells are 
dominant in secondary lymphoid organs [72]. B-1 cells are further classified as B-1a 
cells which produce natural Immunoglobulin (Ig)-M antibodies and B-1b cells which 
respond to T-cell-independent antigens in adaptive humoral immune responses 
[73]. B-2 cells are the most common B cells and are generated in the bone marrow. 
B-2 cells respond to T-cell dependent antigens and are responsible for the adaptive 
humoral immunity. IL-10 producing B cells, called B-10 cells, form part of a broader 
subset of regulatory B cells [74]. 
Winer et al. demonstrated that B cell numbers increase during HF diet in DIO mice 
[46]. In DIO mice, B cell accumulation in VAT is linear to the occurrence of insulin 
resistance. The negative impacts of B cells on glucose metabolism are linked to the 
activation of pro-inflammatory macrophages and T cells and the production of 
pathogenic IgG antibodies. After several weeks on HF diet, class switching from 
IgM+ IgD- to IgG+ increases, especially to pro-inflammatory IgG2c in VAT [46], 
leading to increased levels of IgG2c in spleen and serum of obese mice. 
Accordingly, treatment with a B cell–depleting CD20 antibody attenuates disease, 
whereas transfer of IgG from DIO mice rapidly induces insulin resistance and 
glucose intolerance in an  fragment crystallizable (Fc) -dependent manner [46].  
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1.2 The Hygiene Hypothesis 
Epidemiological studies reported that there are increased rates of disease-related 
allergies such as asthma, rhinitis and dermatitis in developed countries compared to 
developing countries [75]. Numerous cohort studies further showed an inverse 
correlation between helminth infections and allergies, e.g. in children who are 
infected with Schistosoma haematobium [76,77] and Schistosoma mansoni [78–80]. 
In contrast, clearance of helminth infection increases skin test reactivity in children 
[81,82]. Therefore, increased incidence of allergies has been correlated with 
improved hygiene in developed countries and a lower incidence of childhood 
infections. This lack of infection may lead to a dysregulated immune system which 
facilitates the development of allergies and led to the concept of the hygiene 
hypothesis.  
Antihelminthic treatment during pregnancy in a population endemic for schistosome 
and hookworm infections increased the incidence of atopic eczema in the offspring 
[83,84]. In addition, studies in Ecuador and Vietnam have reported that the 
prevalence of skin allergic and allergen skin sensitization were increased in children 
who received long term antihelminthic treatment [81,85]. In line with this, a cross 
sectional study in a poor sanitation area in Vietnam has reported that prevalence of 
allergen skin test sensitization is reduced in a population of children with a high 
prevalence of hookworm infection [86].  
The ‘hygiene hypothesis’ was later postulated not only to explain the inverse 
correlation between the incidence of infections and the rise of allergic diseases but 
also autoimmune diseases. Accordingly, Zaccone et al. reported that the incidence of 
T1D is positively correlated with hygiene conditions [87] (Fig. 4). 
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Figure 4. Inverse correlation between Type 1 Diabetes (T1D) incidence and neglected infectious 
diseases. Red areas represent endemic regions for at least 6 neglected diseases (filariasis, leprosy, 
onchocerciasis, schistosomiasis, soil-transmitted helminths, and trachoma). Yellow areas indicate 
countries with a high incidence of T1D (> 8 per 100 000/year).  
Source: Zaccone P, Fehervari Z, Phillips JM, Dunne DW, Cooke a. Parasitic worms and inflammatory 
diseases. Parasite Immunol. 2006;28: 515–23 [87]. 
 
Mutapi et al. further reported that autoantibody levels of schistosome-infected 
individuals are lower than in infection-free individuals. They also revealed that levels 
of autoantibodies increased in infected individuals after clearance of schistosome 
infection by praziquantel treatment [76]. In another study, it was reported that 
multiple sclerosis (MS) prevalence was inversely correlated with the prevalence of 
Trichuris trichiura infection [88]. Furthermore, a cohort study by Correale et al. 
demonstrated that helminth-infected MS patients show a significantly lower 
progression of MS compared to uninfected individuals [89]. 
By now, a number of studies demonstrated that helminth infections prevent or 
ameliorate autoimmune diseases like T1D, rheumatoid arthritis, chronic 
inflammatory bowel disease, and MS [87,90–93]. Studies in clinical trials are 
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currently testing the beneficial effect of Trichuris suis ova treatment on autoimmune 
diseases.    
1.3 Helminth infections and its beneficial impact on diabetes 
1.3.1 Impact of helminths on type 1 diabetes 
Hübner et al. demonstrated that infection with the filarial nematode Litomosoides 
sigmodontis (L.s.) prevents the onset of T1D in non obese diabetic (NOD) mice. 
Interestingly, the protection was not only given by living worm infection, but also by 
administration of crude worm extract (L.s. antigen). This protection was associated 
with a type 2 immune shift and induction of FoxP3+ Treg cells [92]. Using IL-4 deficient 
NOD mice, which failed to develop a type 2 immune response during L.s. infection, 
Hübner et al. demonstrated that L.s.-infected NOD mice were still protected from T1D 
development. In contrast, depletion of the anti-inflammatory cytokine transforming 
growth factor beta (TGF-β), but not blockade of IL-10 signalling in immunocompetent 
NOD mice, prevented the protective effect of helminth infection on diabetes, 
suggesting that TGF-β is required to provide protection by L.s. infection [93].  
In addition, Cooke et al. demonstrated that Schistosoma mansoni infection or 
administration of S.mansoni eggs or soluble worm antigen (SWA) or eggs antigen 
(SEA) protect NOD mice from onset of T1D [94–96]. This protection was elucidated by 
induction of Th2 immune response and Foxp3 expressing Tregs [95,96]. 
1.3.2 Impact of helminths on type 2 diabetes 
Although a beneficial impact of helminth infections is well known for autoimmune 
diseases like T1D, its impact on the metabolic diseases like insulin-resistant T2D is less 
well studied. 
Epidemiological studies suggested a beneficial effect of helminth infections on 
metabolic diseases. Aravindhan et al. (2010) observed a significant decrease in the 
prevalence of lymphatic filariasis among diabetic subjects in an area that is endemic 
for lymphatic filariasis. Decreased prevalence of lymphatic filariasis among diabetic 
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subjects was further associated with a diminished pro-inflammatory cytokine 
response [97]. 
A study in a rural area in China with a high prevalence of Schistosoma infections 
showed significant lower TG levels in people that had a history of schistosomiasis 
compared to people who were never infected [98]. In addition, people with previous 
schistosome infections had significantly lower levels of adjusted fasting blood glucose, 
postprandial blood glucose, and glycated hemoglobin (Hb)-A1c levels indicating that 
helminth infection may prevent ß-islet cell destruction by reducing metabolic factors 
such as FFA and hyperglycemia [98].   
In line with epidemiology studies in India and China, a recently study in Flores Island, 
Indonesia, has reported an improvement of insulin sensitivity in individuals with soil 
transmitted helminth (STH) infections. The lower body mass index of individuals with 
STH was associated with improvement of insulin sensitivity as indicated by a 
decreased homeostatic model assessment for insulin resistance (HOMAIR) [99]. 
In addition to epidemiological studies, some experimental studies demonstrated an 
improvement of glucose tolerance in DIO mice that were either helminth-infected or 
treated with helminth-derived products. Wu, et al. initially demonstrated that 
Nippostrongylus brasiliensis infection improves glucose tolerance in DIO mice. This 
improvement was associated with increased frequencies of eosinophils in perigonadal 
/ epididymal adipose tissue (EAT) and a reduced body weight and fat mass [44].  
Using the same model, Yang et al. highlighted that glucose tolerance improvement in 
N. brasiliensis-infected DIO mice was associated with a decreased body weight gain 
and upregulation of AAM markers in EAT [100].  
Subsequently, Bhargava et al. demonstrated that administration of soluble egg 
antigen of S. mansoni (LewisX-containing LNFPIII) improves glucose tolerance and 
insulin sensitivity in DIO mice. These effects were associated with increased IL-10 
production in bone marrow-derived macrophages and dendritic cells [101]. 
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The last evidence was shown by Hussaarts et al., who reported that Schistosoma 
mansoni infection and soluble egg antigen (SEA) administration in DIO mice improve 
glucose tolerance and promote type immune responses, eosinophilia, and AAM in 
EAT [102]. 
1.4 Helminth infection and immune regulation 
Helminth parasites infect almost one-third of the world's population, primarily in 
tropical and sub-tropical regions [103,104]. Most helminth infections cause no or only 
mild pathology and only a subset of patients develop severe pathologies. The 
maintenance of an asymptomatic state during helminth infection is due to the 
immunoregulatory capacity of the helminths which involves the induction of multiple 
regulatory cell types and cytokines; while a breakdown of this regulation may cause 
pathology [105].  
Helminths are well known to modulate the immune system by inducing type-2 
immunity which is characterized by T helper (Th) 2 cells and their associated 
cytokines, increased frequency of tissue eosinophils, mucosal mastocytosis, and 
enhanced production of IgE [106]. In addition, helminth infections  induce regulatory 
responses via regulatory T cells (Treg) that secrete the suppressive cytokines IL-10 
and TGF-ß [107] and express molecules such as cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4) or glucocorticoid-induced TNF receptor (GITR) that are involved in 
the suppression of immune responses [65]. Helminth infections have also been 
associated with regulatory B cells (Breg), which can release IL-10 [108].  
This immunomodulation by helminths may not only enable the long-term survival of 
the parasite in the host, but may also affect the response to bystander antigens. 
1.4.1 Th2 immune response 
Generally, helminth parasites induce in their hosts type 2 immune responses which 
are characterized by increased levels of IL-4, IL-5, IL-9, IL-13 cytokines that are in 
general thought to mediate protective responses against helminth parasites [109–
115].  
 Introduction 
20 
 
Th2 immune responses were also proposed to promote wound healing and tissue 
regeneration which can limit the damage due to helminth parasites during their 
trafficking through host tissues [116–119].  
In filarial infection, Th2 differentiation from naïve T cells is initiated after contact 
with live larvae (L)-3 of Brugia pahangi and L.s.[120]. Nevertheless, during filarial 
infection, Th1 immunity is also induced by endosymbiontic Wolbachia bacteria, 
which are present in most human pathogenic filariae, as well as L.s.,  that can be 
released after the death of filariae [121,122]. At ~ 12 days post infection (dpi), L.s. 
infection induces Th2 responses with increased levels of IL-5 and IL-4, which are 
important for filarial elimination and control patency [120,122].  
IL-4 and IL-13 are further suggested to promote wound healing by stimulating innate 
and adaptive immune cells to secrete cytokines, growth factors and angiogenic 
factors that promote fibroplasia and angiogenesis and inhibit classical inflammation 
[119,123].  
L.s. infection was demonstrated to increase the numbers of AAM in their hosts [124]. 
To identify AAM, several markers have been used including cell surface IL-4 receptor-
a (IL-4Ra) and the mannose receptor CD206 in flow cytometriy [125] or 
immunohistology [109]. Gene expression of Arginase-1 (Arg1), Fizz (found in 
inflammatory zone) family member proteins (ChaFFs), including: Fizz1/ Relmα, Ym1, 
and acidic mammalian chitinase (AMCase) are upregulated during nematode 
infection [60]. AAM are activated through IL-4/IL-13 stimulation via the IL-4Rα 
receptor and STAT6 [126]. Through Th2 cytokines induction, several helminth 
antigens were demonstrated promote AAM polarization [127–130]. 
1.4.2 Wolbachia and its role in immune regulation 
An endosymbiotic bacteria of the genus Wolbachia was identified in the 1970s as an 
unusual body in the hypodermis of filarial nematodes [131]. These bacteria are 
found in all developmental stages and are abundant in adult worms [132]. The 
majority of filarial species including the major filarial parasites of 
humans: Wuchereria bancrofti, Onchocerca volvulus and Brugia malayi as well as the 
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murine filarial nematode L.s. harbor Wolbachia [132]. However, some filarial 
nematodes including the rodent filaria Acanthocheilonema viteae and the deer 
parasite Onchocerca flexuosa are free from Wolbachia [132]. Similarly, the human 
pathogenic filaria Loa loa does not contain Wolbachia [133]. As an endosymbiont, 
Wolbachia are essential for worm fertility, reproduction, larval molting and survival. 
Depletion of Wolbachia prevents filarial development, fertility and viability, which 
offers a novel approach for treating filarial diseases using antibiotics such as 
doxycycline [134,135]. 
The presence of Wolbachia in filarial nematodes can provoke inflammation in the 
filariae-infected host [136–138] through TLR-2/6 activation [138], resulting in 
increased production of IL-6, TNFα, and IL-1β [139]. The Wolbachia surface protein 
of B. malayi induced increased frequencies of Th17 cells and Th1 cytokines like 
interferon-γ (INFγ) and IL-2 and reduced the frequency of Tregs, Th2 cytokines like IL-
4 and anti-inflammatory IL-10 and TGF-β levels in culture supernatants of 
splenocytes [140]. Therefore, classical antihelminthic treatment (e.g. diethyl 
carbamazine /DEC) could induce adverse drug reactions due to the Wolbachia 
release from dying filariae [139].   
Depletion of Wolbachia by doxycycline does not only eliminate adult filarial worms 
and microfilariae, but was also shown to improve lympangiogenesis, lymphatic 
endothelial proliferation, and dilation of lymphatic vessels [141]. 
1.5 Helminth-derived products 
Several immunomodulatory helminth-derived molecules have been described over 
the past decade [142]. Studies about those molecules have two beneficial aspects: (1) 
since those molecules are used by parasites to enable their survival—their 
neutralization would be a strategy to eliminate helminth infections [143] and (2) their 
potential immunosuppressive effect could be used to counter inflammatory 
disorders.  
Different helminth-derived products have recently been demonstrated to prevent the 
development of inflammatory diseases in mouse models. Such a molecule is ES-62, a 
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glycoprotein from the filarial nematode Acanthocheilonema viteae which modulates 
cellular activity via TLR4 [144–146]. Administration of this molecule prevents the 
development of collagen-induced arthritis, oxazolone-induced contact sensitivity and 
ovalbumin-induced airway hypersensitivity in mice through the inhibition of B-2 cell 
proliferation and the induction of B-1 cell-dependent IL-10 secretion. In addition, ES-
62 promotes type 2 anti-inflammatory responses through TLR4-dependent activation 
of APCs. This molecule also inhibits mast cell degranulation and inflammatory 
mediator release via TLR4-dependent activation [146]. 
Cystatin, a cysteine protease inhibitor (CPI) from helminths is another well studied 
immunomodulatory molecule, which attenuates Ovalbumin airway hypersensitivity as 
well as Dextran sulfate sodium (DSS)-induced colitis [147]. Nematode cystatins inhibit 
proteases involved in antigen processing and presentation and therefore reduce T cell 
responses. Nematode cystatins were further described to promote IL-10 and Th2 
cytokine secretion by macrophages [147,148].  
In addition, administration of a crude extract from L.s. (LsAg) induced type 2 immune 
responses and triggered IL-10 production in NOD mice and delayed diabetes onset 
when administered at 6 weeks of age [92].   
Given that helminth-derived products have been shown to modulate immune 
responses, the study of those molecules may provide new candidates for treatment 
of inflammatory disorders including obesity-induced insulin resistance. 
1.6 The L. sigmodontis mouse model 
The rodent filarial nematode L. sigmodontis is an excellent model to investigate 
immune responses during filarial infections. While human-pathogenic filariae like 
Brugia spp. and Oncocerca spp. do not develop in immunocompetent wildtype (WT) 
mice [149–151], L. sigmodontis is able to complete its life cycle in immunocompetent 
BALB/c mice, where the infection results in patent infections with circulating 
microfilariae [149,152]. The infection with L. sigmodontis in BALB/c mice mimics 
hereby immune responses as they occur during helminth infections in humans. Thus, 
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L. sigmodontis is an ideal model for filarial infection in humans and induces type 2 
immune responses [149,153], Tregs and IL-10 [62,113,114].  
1.6.1 L. sigmodontis life cycle 
The life cycle of L.s. is illustrated in Fig. 5. The tropical rat mite Ornithonyssus bacoti 
transfers with its blood meal infectious L3 larvae, which migrate from the entrance 
site in the host skin via the lymphatic vessels to the pleural cavity. 
Approximately 60% of the inoculated L3 larvae are eliminated before they reach the 
pleural cavity which occurs 2-6 dpi [149]. The L3 which reach the pleural space 
develop into L4 larvae around 8-12 dpi and molt into adult worms around 30dpi. 
After mating of male and female adult worms, filarial embryos develop in the female 
filariae. Starting around day 50 to 55 post infection, microfilariae (Mf) circulate in the 
peripheral blood (Hoffmann, Petit et al. 2000). 
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Figure 5. Life cycle of Litomosoides sigmodontis: during natural infection mice are infected with L3s 
by the bite of infected tropical rat mites (Ornithonyssus bacoti). After infection, L3 larvae migrate via 
the lymphatic system to the pleural cavity within 2-6 days post infection (dpi). In the pleural cavity, 
L3 larvae molt into the L4 stage between 8-12 dpi, become adults after another molt at 25-30 dpi. 
After mating, female adult worms start to release microfilariae which circulate in the peripheral 
blood by 50 dpi. 
Source: Hübner MP, Torrero MN, McCall JW, Mitre E. Litomosoides sigmodontis: a simple method to 
infect mice with L3 larvae obtained from the pleural space of recently infected jirds (Meriones 
unguiculatus). Exp Parasitol. 2009;123: 95–8[154]. 
1.7 Aims and Objectives of this work 
Although a protective role of filarial infections is well accepted for autoimmune 
diseases like T1D, it is not known whether filarial infections impact the development 
of metabolic diseases like insulin-resistant in T2D.  
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Despite first epidemiological and experimental studies that investigated the impact of 
helminth infections on the metabolic syndrome, experimental studies using filarial 
nematodes have not been conducted yet and the protective mechanism mediated by 
helminth infection is still insufficiently understood. The major aim of this thesis was 
therefore to investigate whether infection with the tissue–invasive rodent filarial 
nematode L. sigmodontis and administration of LsAg protect against HF diet-induced 
insulin resistance in DIO mice and to elucidate the protective mechanism. As pro-
inflammatory cytokines and CAM are important for the induction of insulin resistance 
in mice fed on a HF diet, we hypothesized that filarial infection and its derived 
product reduces the pro-inflammatory immune response and maintains the 
frequency of AAM in adipose tissue, thus ameliorating insulin resistance. Since 
eosinophils have been previously shown to play a key role in maintaining AAM to 
improve insulin sensitivity, an additional aim of this study was to address whether 
eosinophil and AAM are required to improve insulin sensitivity in L.s. infected DIO 
mice.  
Since accumulation of B cells in VAT of DIO mice promotes insulin resistance through 
pathogenic IgG production, we further hypothesized that L.s. infection promotes 
insulin sensitivity by modulating B cells in VAT of DIO mice, which should be 
addressed using flow cytometry. 
As excessive adipose tissue mass in obesity is a major risk factor for initiating insulin 
resistance, the impact of L.s. infection and LsAg administration on adipogenesis was 
planned to be investigated. 
Furthermore, over the past few years, brown adipocytes became a new target to 
counter obesity and metabolic-related diseases by its capacity to control energy 
homeostasis by dissipating chemical energy and increasing energy expenditure [155–
157]. Interestingly, recent studies reported that helminth-associated features such as 
eosinophils, AAM and type 2-associated cytokines are correlated with browning of 
white adipose tissue [54,55,158]. Thus, the hypothesis that L.s. infection and LsAg 
administration promote browning of adipose tissue and increase energy expenditure 
was to be analyzed. 
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To obtain a better understanding regarding the molecular mechanism by which L.s. 
infection and LsAg administration impact insulin signaling, multiple gene expression 
analyses of EAT were supposed to be performed using polymerase chain reaction 
(PCR) array. 
Thus, the overall aim of this thesis was to investigate whether L.s. infection and/or 
LsAg treatment improve insulin sensitivity in DIO mice and to analyze several 
potential protective mechanisms.  
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2. Materials and Methods 
2.1 Animals and animal care 
All mice used in this study were maintained at the animal facility of the Institute for 
Medical Microbiology, Immunology and Parasitology, University Hospital of Bonn.  
Mice were housed in individually ventilated cages at a 12-hour day/night cycle with 
free access to food and water. The experiments in this thesis were performed using 
male BALB/c, ΔdblGATA on a BALB/c background and C57BL/6J mice. BALB/c and 
C57BL/6J mice were purchased from Janvier Labs (La Genest St. Isle, France). 
ΔdblGATA mice were originally obtained from Jackson Laboratory (Bar Harbor, ME, 
USA) and bred and housed at the central animal facility of the University Hospital of 
Bonn (Haus für Experimentelle Therapie). HF diet which provides 60% of calories from 
fat was purchased from Research Diets, Inc., Brogaarden, Denmark. HF diet feeding 
was started at 6-8 weeks of age. All protocols were approved by the Landesamt für 
Natur, Umwelt und Verbraucherschutz, Cologne, Germany. 
2.1.1 Glucose tolerance test  
Six hours before the glucose tolerance test (GTT), food was removed from the cages. 
After 6 hours of fasting, blood glucose levels were measured from the tail vein using 
a standard blood glucose meter (Accu-Check Advantage, Roche Diagnostics GmbH, 
Mannheim, Germany) to determine fasting glucose. For glucose challenge, mice 
were injected intraperitoneally (i.p.) with 2g glucose monohydrate (Merck, 
Darmstadt, Germany) solution per kg body weight [159]. At 15, 30, 60, 90, and 120 
minutes post glucose injection, blood glucose levels were measured from the tail 
vein. 
2.1.2 Insulin tolerance test  
Before the insulin tolerance tests (ITT) were performed, the food was removed from 
the cages. The first glucose measurements were taken immediately before the 
insulin injection. Glucose levels of mice were determined from blood taken from the 
tail vein using surgical scissors. After the baseline glucose level measurement, insulin 
(0.001unit/g body weight) was injected i.p. [159]. The blood glucose levels were 
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observed overtime at 15, 30, 60, 90, and 120 minutes using a standard blood glucose 
meter (Accu-Check Advantage, Roche Diagnostics GmbH, Mannheim, Germany). 
2.1.3 Cold tolerance test 
For cold tolerance test, mice were placed in a 5oC temperature room for a maximum 
of 4 hours. The body temperature was measured from the mid-dorsal body surface 
using a ThermoScan thermometer (PRO 4000, Braun, Kronberg, Germany) as 
described previously [160]. The measurement was performed before, 1, 2, 3 and 4 
hour(s) of cold exposure.   
2.1.4 Euthanasia of mice 
At the determined time point of experiment, euthanasia was performed. Mice were 
anesthetized per isoflurane (Abbot, Wiesbaden, Germany) inhalation.  Blood was 
then taken from the retro-orbital vein using micro-haematocrit capillaries (Brand, 
Wertheim, Germany) and transferred into 1ml disodium ethylenediaminetetraacetic 
acid (EDTA)-containing tubes (Kabe Labortechnik, Nümbrect-Elsenroth, Germany). 
Afterwards, mice were killed using an overdose per inhalation of isoflurane and were 
fixed on a surgical board. The skin and peritoneum were gently dissected and the 
EAT was removed from the intra abdomen. Subcutaneous adipose tissue (ScAT) was 
collected by dissecting fat under the dorsal skin. For brown adipose tissue collection, 
interscapular brown adipose tissue was taken. Adipose tissues for Fluorescence-
Activated Cell Sorter (FACS) analysis were collected in DMEM-low glucose medium 
(Gibco, life technologies, US) containing 1g/L D-glucose, 4mM L-Glutamine, 25mM 
HEPES, 1g/ml BSA and 1% penicillin-streptomycin. For quantitative PCR (qPCR) 
analysis, small tissue parts were collected and immediately snap frozen in liquid 
nitrogen. Finally, the thoracic cavity was opened to confirm the presence of adult 
worms.  
2.1.5 L.s.infection 
L.s. infection was performed by natural infection as was previously described [161]. 
If not stated otherwise, mice were infected at 8-10 weeks of age, 2 weeks after the 
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onset of HF diet. During natural infection, infective L3 larvae are transmitted with 
the blood meal of infected O. bacoti mites and migrate to the thoracic cavity where 
they molt into adult worms (~30dpi). At the time of necropsy, infection status of 
mice was confirmed by screening for adult worms in the thoracic cavity. 
2.2 LsAg preparation 
L.s. adult worms were harvested from the pleural cavity of L.s.-infected-cotton rats 
and transferred into a glass potter. By adding phosphate buffer saline (PBS), worms 
were homogenized until a suspension was obtained. This suspension was centrifuged 
for 10 minutes at 3200g and 4°C. The supernatant was collected and the protein 
concentration was measurement by BCA Protein assay kit (Thermo scientific, 
Rockford, USA). Those procedures were performed under sterile conditions. 
2.3 Helminth-derived product administration 
At the determined time, each group of DIO mice were injected i.p. with 2µg/mouse of 
ES-62, CPI, or LsAg. DIO controls were injected with PBS. Achanthocheilonema vitae 
derived ES-62 was kindly provided by Prof. Dr. William Harnett (University of 
Strathclyde, UK). Litomosoides sigmodontis derived CPI and Abundant Larva 
Transcript (ALT) were kindly provided by Dr. Simon Babayan (University of Glasgow, 
UK). 
2.4 Isolation of the stromal vascular fraction 
Epididymal fat pads from male mice fed a normal chow diet or HF diet were excised 
and minced in DMEM-low glucose (Gibco, life technologies, US) containing 1g/L D-
glucose, 4mM L-Glutamine, 25mM HEPES, 1g/ml bovine serum albumin (BSA) and 1% 
penicillin-streptomycin. Minced tissue was transferred to 2ml medium containing 
1.5mg/ml Collagenase-P (Roche, Mannheim) and then incubated at 37°C for 20-30 
minutes with continuous shaking. After incubation, the tissue suspension was washed 
with DMEM-low glucose (without supplements) and was centrifuged at 300g for 5 
minutes to remove the collagenase and separate floating fraction from the stromal 
vascular fraction (SVF) pellet. After retaining SVF, the floating fraction were digested 
for a further 10 minutes in medium containing collagenase, and the SVF were pooled 
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through the filter for FACS analysis. After centrifugation, the SVF pellet was incubated 
for flow cytometric analysis in 1ml 1x red blood cell lyses buffer (eBioscience) for 5 min 
and was afterwards washed with DMEM-low glucose (without supplement). The cells 
were blocked with anti-CD16/anti-CD32 antibodies in FACS buffer (1X DPBS without 
Ca2+ and Mg2+, 2mM EDTA, and 1% FCS) at a final concentration of 0.5-1 μg/106 cells 
for 30 minutes. Before antibody staining, the cell suspension was filtered through a 
100µm filter, and the volume was adjusted to obtain 1 million cells per FACS tube.  
2.5 Flow cytometry 
To analyze the cell composition in SVF of EAT, cell surface markers were stained for 
30 minutes at 4°C with rat anti-mouse F4/80 PerCP-Cy5.5, CD4 FITC, CD11c APC, CD19 
PE, CD23 FITC, CD5 PE-Cy-7-A, Gr1 PerCP-Cy5.5 (all eBioscience), and Siglec-F PE (BD 
Bioscience). To identify intracellular proteins, cells were fixed with 
fixation/permeabilization buffer (eBioscience) overnight, washed and blocked in PBS 
containing 1% BSA (PAA) and rat Ig (1µg/ml, Sigma, St. Louis, MO, USA). For RELMα 
staining, fixed cells were incubated in permeabilization buffer (eBioscience) and were 
stained with rabbit-anti-mouse RELMα (Peprotech, Rocky Hill, NJ, USA). After a 
washing step, cells were stained with a secondary antibody (goat anti-rabbit 
Alexa488, Invitrogen, Carlsbad, CA, USA). Tregs were analyzed after overnight fixation 
and permeabilization and staining with CD4 FITC and Foxp3 PE (all eBioscience). Data 
were acquired using a BD FACS Canto and analyzed with BD FACS DIVA software. 
2.6 IgG2a measurement by Enzyme-linked immunosorbent assay (ELISA) 
IgG2a (BD Pharmingen) concentrations were measured by sandwich ELISA according 
to the manufacturers direction. Polysorb ELISA plates (Nunc, Roskilde, Denmark) were 
first coated with primary antibodies in PBS or coating buffer (Na2HPO4 0.1M, Merck, 
in distilled aqua pH 7.0) for overnight at 4 oC. Plates were then blocked with PBS/1% 
BSA for a minimum of 2 hours at RT and washed three times with PBS/0.05% Tween 
20 (Sigma-Aldrich). 50μl of blood serum were added for a minimum of 2 hours at RT 
or at 4°C overnight. The detection antibody was added for 2 hours. Following 20 
minutes of incubation with horseradish peroxidase (HRP)-streptavidin (R&D Systems) 
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and tetramethylene benzidine (TMB) (Carl Roth GmbH, Karlsruhe, Germany), the 
color reaction was stopped with 1M H2SO4 (Merck) and optical density (OD) was 
measured at 450nm using the SpectraMAX 340 microplate reader and data was 
analyzed with the Softmax Pro software (both Molecular Devices, Sunnyvale, CA, 
USA). 
2.7 Adipose tissue histology staining 
Adipose tissue was fixed in 4% paraformaldehyde (Otto Fischar GmbH, Saarbrücken, 
Germany) for at least 24 hours. After fixation, tissue was dehydrated with ethanol and 
then embedded in paraffin for cutting. The paraffin block was cut using a microtome. 
The cut sections of 5µm thickness were placed on warm water to flatten out and 
were then transferred to glass slides. For dewaxing, sections were dipped into xylol 
and then dipped into a series of 100%, 90%, 80%, 70%, and 50% ethanol. Afterwards, 
the tissue sections were dyed with hematoxylin solution for 10 minutes, and then 
washed under tap water for 10 minutes. Subsequently, tissue sections were dipped 
into distilled water and dyed using 0.1% eosin for 3 minutes afterwards. The stained 
tissue was dipped in 96% ethanol and 100% xylol respectively. To make the section 
permanent, the stained section was mounted. 
2.8 Ribonucleic acid (RNA) isolation and Real-time PCR 
To extract RNA from tissues, about 30mg of epididymal fat pads were collected, snap 
frozen in liquid nitrogen and stored at -80°C until RNA isolation. RNA was extracted 
from adipose tissue using Trizol (Invitrogen, US) in combination with the RNeasy mini 
kit (Qiagen, Hilden, Germany). Frozen adipose tissues were transferred into 2ml 
innuSPEED Lysis Tubes W (Analytik-Jena) containing Trizol. Tissues were disrupted with 
the Precellys homogenizer for 10 seconds (6000rpm). Tissue suspensions were then 
transferred into new tubes and were washed with 70% ethanol (1:1). Subsequent 
procedures used RNeasy mini columns following standard protocols of the RNeasy 
mini kit from Qiagen. Quality of extracted RNA was assessed by spectrophotometric 
determination of the OD260/OD280 ratio. Template-RNA was quantified by the OD260 
value. At least 4.2µg/ml of total RNA was reverse transcribed with an Omniscript RT Kit 
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(Qiagen, Hilden, Germany) according to the manufacturer’s instructions with oligo-d(T) 
primers (Roche, Mannheim). Real Time PCR was performed in a 20µl reaction volume 
containing 2µl 10x reaction buffer, 5mM Deoxynucleotide (dNTP) mix, 0.2µl SYBR 
green (diluted 1:1000), 0.1µl Hotstar Taq and 2µl complementary deoxyribonucleic 
acid (cDNA), and a standardized concentration of Mg2+ and primer, using a Rotorgene 
cycler (Corbett life science). For gene expression quantification, a relative 
quantification method was used (ΔΔCt). List of primer sequences are presented in 
Table S4. 
2.9 PCR array  
Deoxyribonucleic Acid (DNA)se treatments were performed to avoid DNA 
contamination of the RNA isolate. Before cDNA syntheses were performed, RNA 
integrities were checked using RNA StdSens chips from Experion (Bio-Rad, US). RNA 
quality indicator (RQI) >7 was recommended and used to be continued for PCR array 
performance. cDNA synthesis was performed as described with the RT2 PreAMP cDNA 
Synthesis Kit (Qiagen, Hilden, Germany) protocol. After cDNA was obtained, 27µl 
preamplified cDNA template was diluted to 111µl by adding 84µl of destilled H2O. For 
PCR amplification reaction, 1275µl 2x SABioscience RT2 qPCR SYBR Green master Mix, 
102µl diluted preamplified cDNA and 1173 destilled H2O were mixed. For PCR 
running, 20µl of PCR amplification reactions were pippeted into 100-well Disc formats 
of the Mouse Diabetes PCR Array (PAMM-023, Qiagen) or Mouse Insulin Resistance 
PCR Array (PAMM-156Z Qiagen), and were run with the following real-time thermal 
cycle program: 95oC, 10 min; 40 cyles (95oC, 15s; and 60o, 60s). PCR array data were 
analyzed using the online software of RT2Profiler PCR Array Data Analysis version 3.5. 
The CT values were normalized to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and beta-2-microglobulin (B2m). 
2.10 3T3-L1 cell culture and treatment 
3T3-L1 cells, a murine fibroblast/pre-adipocyte cell line, were obtained from the 
German Diabetes Centre, Düsseldorf, and the Institute of Pharmacology and 
Toxicology, University Hospital of Bonn. Cells were seeded in 96 well plates with 
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Dulbecco’s modified Eagle’s medium (DMEM)-high glucose (PAA) containing 10% calf 
serum (PAA), 1% penicillin/streptomycin and 1mM Natrium pyruvat (PAA). 
Differentiation was induced 2 days after reaching 100% confluence (d0). For induction 
of differentiation, 100µL DMEM-high glucose medium containing isobutyl-
methylxanthine (0.5mM), dexamethasone (1µM) and insulin (10µg/ml) (all from 
Sigma Aldrich) were added to the 3T3-L1 cells. Every other day (at d2, d4, d6, d8), 
medium was exchanged with insulin medium (DMEM-high glucose containing 10% 
calf serum, 1% penicillin/streptomycin, 1mM sodium pyruvate and 10µg/ml insulin). 
Positive adipogenesis controls were made by adding troglitazone (10µmol/L) at d0. 
Treated cells received 0.25µg LsAg /100µl at d0, d2, d4, d6, d8. At d9, adipogenesis 
assays were performed. 
2.11 Oil Red O staining  
Lipid droplet formation in cells was analyzed by Oil Red O (Sigma) staining. At d8, 
culture medium was removed and cells were fixed for at least 1h with 10% 
formaldehyde. After fixation, cells were stained with Oil Red O solution (a mixture of 
three parts of 0.5% (w/v) Oil Red O in isopropanol and two parts of water) for 30 
minutes at room temperature followed by washing with water. Cells were kept in PBS 
and were photographed. For analysis of lipid droplet formation, 100 µL 96% 
isopropanol was added per well and cells were incubated on a shaker (300 rpm) at 
room temperature for 30 minutes. Absorbance was measured using SpectraMAX 340 
microplate reader at 540nm and data was analyzed with the Softmax Pro software 
(both Molecular Devices, Sunnyvale, CA, USA). 
2.12 Triglyceride assay 
The triglyceride assay was performed using the adipogenesis assay kit from Sigma. In 
brief, at d11, the 3T3-L1 murine pre-adipocyte cells were seeded in 96 well-plates. 
After differentiation and treatment, medium was removed and cells were washed 
once with PBS at room temperature. 100 μL of Lipid Extraction Buffer was added to 
the culture wells and the plate was incubated for 30 minutes at 90–100°C to extract 
lipids from the cells. The plate was then placed at room temperature and shaken for 1 
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minute to homogenize the solution. 5–50μL of the lipid extracts were transferred to a 
new 96 well plate and the Adipogenesis Assay Buffer was added to a 50µl final 
volume. To convert TG to glycerol and fatty acids, 2μL of Lipase solution was added to 
each sample and standard well, and the plate was incubated for another 10 minutes 
at room temperature. As final step, 50µl of the master mix reaction were added to 
each well. After 30 minutes of incubation at room temperature with shaking, the 
absorbance was measured at 570nm wavelength to measure TG levels using a 
SpectraMAX 340 microplate reader. The data was analyzed with Softmax Pro 
software (both Molecular Devices, Sunnyvale, CA, USA). 
2.13 MTT assay 
Two days post confluence, cells were treated with 0.25µg/100µl LsAg, 10µmol/l 
troglitazone (Sigma) and PBS as control. After 2 days of incubation, the medium was 
discarded and cells were washed with PBS. Cells were then incubated in insulin 
medium containing 0.5mg/ml Thiazolyl (Carl Roth GmbH) at 37°C for 3-4 hours. After 
incubation, medium was aspirated. For analysis, formazan was dissolved by adding 
100µL Dimethyl sulfoxide (DMSO) (Sigma) and the absorbance was read at 490nm 
after an incubation of 5 minutes. Percent viability data was calculated for each well by 
normalizing to the median absorption of PBS-treated control cells (set to 100% 
viability).  
2.14 Statistics 
Data were analyzed for statistical significance using GraphPad Prism software Version 
5.03 (GraphPad Software, San Diego, CA, USA). Mann-Whitney-U-test was applied to 
test differences between two unpaired groups for statistical significance. For 
comparison of more than two groups, differences were tested for statistical 
significance using the Kruskal–Wallis test, followed by Dunn’s post hoc multiple 
comparisons test. P values of < 0.05 were considered as significant. PCR array data 
analyses were performed using the online software provided by SABioscience 
(Frederick, USA). The p values were calculated based on a Student’s t-test of the 
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replicate 2^(-Delta Ct) values for each gene in the control group and treatment 
groups, and p values < 0.05 were considered as significant. 
2.15 Referencing methods 
References in this thesis were managed using the Mendeley desktop version 1.13.8 
software (Mendeley Ltd, London, UK), licensed for free.  
2.16 Text processing  
Word and tabular processing were performed with Microsoft Office 2013 (Microsoft, 
USA), licensed for private. This work is written, grammar and spell-checked in 
American English. 
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Framework Programme FP7/2007–2013 under Research Executive Agency Grant GA 
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3. Results 
3.1 L.s. infection improves glucose tolerance in diet-induced obese mice  
Low grade chronic inflammation in visceral adipose tissue due to obesity plays an 
important role in the induction of insulin resistance [162]. In contrast, helminth 
infection is associated with type 2 suppressive immune responses and induces 
regulatory T-cells, eosinophils and AAM [163]. To investigate whether L.s. infection 
improves insulin sensitivity in DIO mice, experiments using L.s.-infected and uninfected 
BALB/c mice were conducted. Male BALB/c mice were maintained on a HF diet that 
provided 60% of calories from fat for 10 weeks to induce insulin resistance, and a 
subset of animals were infected with L.s. two weeks after the onset of HF diet (Fig. 6A). 
During HF diet feeding, both L.s.-infected and control mice developed body weights 
exceeding 30g after 10 weeks on HF diet. At 7 and 8 weeks after the onset of HF 
feeding, the body weights of L.s.-infected mice were lower than of uninfected controls 
(Fig. 6B). However, in repeat experiments this difference was not observed and body 
weights in this experiment were not different at 9 and 10 weeks on HF feeding 
anymore (Fig. 6C).  
A glucose tolerance test revealed that blood glucose levels of L.s.-infected DIO mice 
peaked 15 min post glucose injection while blood glucose levels in control mice 
reached their maximum after 30 minutes (Fig. 6D). At 60 minutes post glucose 
injection, blood glucose levels of L.s.-infected DIO mice declined, while blood glucose 
levels in uninfected DIO mice remained high, suggesting an improved glucose 
tolerance in L.s.-infected DIO mice (Fig. 6D). Blood glucose levels were significantly 
reduced in L.s.-infected DIO mice at all time points measured 15-120 minutes post 
glucose challenge. Accordingly, the area under the curve (AUC) of the glucose 
tolerance test in L.s.-infected DIO mice was significantly lower compared to uninfected 
DIO mice (Fig. 6E). Despite the improved glucose tolerance in L.s.-infected DIO mice, 
insulin tolerance was not significantly improved by L.s. infection. (Fig. 6F,G). 
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Figure 6. L.s. infection improves glucose tolerance in DIO mice. A) Schema of the experimental set 
up. B) Body weight development of L.s.-infected and control mice maintained on a 60% HF diet. C) 
Body weight of L.s.-infected and control mice before the glucose tolerance test. D) Blood glucose 
levels over time following i.p. glucose challenge (glucose tolerance test) in L.s.-infected BALB/c mice 
and uninfected controls that received a HF diet for 10 weeks. E) Area under the curve obtained from 
the glucose tolerance test. F) Blood glucose levels over time following i.p. insulin challenge (insulin 
tolerance test) in L.s.-infected BALB/c mice and uninfected controls that received a HF diet for 12 
weeks. G) Area under the curve obtained from the insulin tolerance test. A-D, representative data of 
one out of three independent experiments with at least 6 animals per group. Statistical significance 
was determined using Mann-Whitney-U-test. Data are expressed as means + SEM *p<0.05; **p < 
0.01 
 
3.2 L.s. infection increases the frequency of eosinophils and alternatively activated 
macrophages within EAT of DIO mice 
During obesity, alterations of the cellular composition within the EAT occur 
[21,164,165]. Classically activated macrophages and B cells infiltrate into the EAT, 
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which is accompanied by the loss of AAM and eosinophils [41,44,46] and leads to low 
chronic inflammation and results in insulin resistance. Thus, we investigated whether 
L.s. infection alters the cellular composition in the SVF of EAT in DIO mice.  
FACS analyses of the SVF from EAT showed that L.s.-infected DIO mice had a 
significant increased frequency of Siglec-F+ eosinophils (DIO controls: 2.84%, L.s.-
infected DIO mice: 11.32%). RELMα mean fluorescence intensity as well as frequency 
of RELMα+ macrophages was increased in macrophages from L.s.-infected DIO mice 
compared to uninfected DIO controls (DIO controls: 10.57 %, L.s.-infected DIO mice: 
24.78 %), while the frequency of macrophages per se did not change (Fig. 7A, B). 
 
Figure 7. EAT of L.s.-infected DIO mice are characterized by increased frequencies of eosinophils 
and alternatively activated macrophages. A) Gating strategy to identify RELMα mean fluorescence 
intensity of F4/80+ macrophages and frequencies of RELMα+ macrophages. B) Frequencies of 
eosinophils, macrophages, and RELMα+ macrophages within the SVF of EAT of L.s.-infected and 
uninfected mice that received a HF diet for 10 weeks. Statistical significance was determined using 
Mann-Whitney-U-test. Data are expressed as means + SEM. *p < 0.05; **p < 0.01. 
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3.3 L.s. infection restricts the frequency of B cells but increases B1 cell subsets in 
epididymal adipose tissue during HF diet 
As described by Winer et al., B cells promote insulin resistance in DIO mice by 
producing pathogenic IgG2 antibodies [46]. B cell subsets were therefore analyzed in 
EAT of L.s.-infected DIO mice and DIO controls (Fig. 8A). As expected, L.s.-infected DIO 
mice had significantly reduced frequencies and total numbers of CD19+ B cells 
compared to uninfected DIO controls (Fig. 8B, C). Interestingly, the frequency of B 
cells that represent the B1 cell subset (CD19+ CD5+ CD23-) was higher in L.s.-infected 
DIO mice compared to DIO controls (Fig. 8D). In line with the reduction of B cells in 
EAT of L.s.-infected DIO mice, the level of potential pathogenic total IgG2a antibodies 
was significantly lower compared to uninfected DIO controls (Fig. 8E). Those results 
suggest that L.s. infection restores a cellular composition within EAT that is 
characterized by increased frequencies of eosinophils and AAM, while B cells are 
restricted, which may reduce inflammation and improve glucose tolerance.   
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Figure 8. B cell frequency within EAT of L.s.-infected DIO mice are reduced compared to DIO 
controls. A) Gating strategy to identify B cells and B cell subsets. B) Frequency of B cells in SVF of EAT 
(C), total number of B cells and (D) frequency of B cells with B1 phenotype within the SVF of EAT of 
L.s.-infected BALB/c mice and controls after 10 weeks of HF diet. (E) Total IgG2a antibody levels in 
blood plasma. Statistical significance was determined using Mann-Whitney-U-test. Data are 
expressed as means + SEM. *p < 0.05; **p < 0.01. 
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3.4 Absence of eosinophils impairs glucose tolerance improvement by L.s. infection 
Davina Wu et al. demonstrated that eosinophils play a major role in the improvement 
of insulin sensitivity in DIO mice by maintaining AAM in the adipose tissue via IL-4 
[44]. Since our earlier finding showed an increased number of eosinophils in EAT of 
L.s.-infected DIO mice (Fig. 6B), we investigated using eosinophil-deficient ΔdblGATA 
mice, whether the improvement of glucose tolerance in L.s.-infected DIO mice 
depended on eosinophils.  
Glucose tolerance tests in both L.s.-infected and uninfected ΔdblGATA mice showed a 
worsened glucose tolerance in comparison to both infected and uninfected WT mice 
(Fig. 9A, B). While L.s. infection improved glucose tolerance in WT mice (AUC, 
p=0.055), this effect was not given in ΔdblGATA mice (Fig. 9A, B), suggesting that 
improvement of glucose tolerance by L.s. infection is dependent on eosinophils.  
 
 
Figure 9. Improvement of glucose tolerance by L.s. infection is dependent on eosinophils. A) 
Kinetic of blood glucose levels after i.p. glucose challenge and B) area under the curve (AUC) from 
the glucose tolerance test (GTT) in L.s.-infected and uninfected ΔdblGATA mice and wild type (WT) 
controls after 14 weeks of HF diet. A and B show representative data of one out of two independent 
experiments. Statistical significance was determined using Kruskal-Wallis followed by Dunn’s 
multiple comparisons test. Data are expressed as means + SEM. *p<0.05. 
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3.5 The beneficial Impact of L.s. infection on glucose tolerance in diet-induced obese 
mice is dependent on the time point of infection 
Although glucose tolerance was improved in L.s.-infected DIO mice at 8 weeks post 
infection (Fig. 6D,E), experiments at different time points of infection demonstrated 
that the glucose tolerance was not improved at all time points of infection. Given that 
the immune response to L.s. infection is influenced by the L.s. life cycle, GTTs were 
performed at several time points of infection from 7 to 16 weeks post L.s. infection. 
Interestingly, each time point of infection had unique patterns for the impact on 
glucose tolerance in DIO mice (Fig. 10 and 11). At 7-8 weeks post infection, 
immediately before the onset of microfilaremia, glucose tolerance was improved as 
was shown by reduced area under the curve levels of L.s.-infected and uninfected DIO 
mice (Fig. 11), while 9-10 weeks post infection did not give consistent improvements 
of glucose tolerance in L.s.-infected mice. However, the improvement of glucose 
tolerance in L.s.-infected mice consistently returned at 11 weeks post infection (Fig. 10 
and 11). Nevertheless, we found that the improvement disappeared after 13 weeks of 
infection, with one exception found at 16 weeks post infection (Fig. 10, 11). These 
findings indicate that the beneficial impact of L.s. infection on glucose tolerance is 
dependent on the time point of infection, which provided at 7-8 wpi and 11 wpi the 
best improvements of glucose tolerance (Fig. 10 and 11).  
Inflammatory immune responses caused by the release of microfilaria into the 
peripheral blood were suspected to be the reason for the vanished improvement of 
glucose tolerance at 9-10 wpi (63-70dpi), as pro-inflammatory immune responses can 
be induced by microfilariae [166]. However, no microfilariae were detected in the 
peripheral blood at 9-10 wpi (data not shown), suggesting that microfilaremia may be 
reduced during HF diet. Further investigation is required to understand the correlation 
between the time point of infection and glucose tolerance improvement and the 
underlying mechanism.  
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Figure 10. Glucose tolerance test (GTT) results of DIO mice at several time points of infection. 
Blood glucose levels over time are shown following i.p. glucose injection of L.s. infected and 
uninfected DIO mice at indicated time points of infection. The GTT curves of the top two rows were 
obtained from the same experiments. At least 5 mice per group were used in all experiments. 
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Figure 11. Improvement of glucose tolerance is dependent on the time point of L.s. infection. Area 
under the curve (AUC) obtained from glucose tolerance tests performed of L.s.-infected and 
uninfected DIO mice at indicated time points of infection. The AUCs of the top two rows were 
obtained from the same experiments. Statistical significance was determined using Mann-Whitney-
U-test. Data are expressed as means + SEM. 
 
3.6 L.s. infection induces an anti-inflammatory immune respose, insulin signaling and 
reduces adipogenesis 
Further investigation was performed to analyze expression of 84 genes using a PCR 
Array (SABioscience) from EAT of L.s.-infected animals and controls that received a HF 
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the helminth-mediated modulation of the immune responses within the adipose 
tissue of DIO mice.  
         7wpi (49dpi)
0
10000
20000
30000
40000
50000 p= 0.11
a
re
a
 u
n
d
e
r 
c
u
rv
e
 (
A
U
C
)
       10wpi (70dpi)
0
10000
20000
30000
40000
50000
a
re
a
 u
n
d
e
r 
c
u
rv
e
 (
A
U
C
)
          11wpi (77dpi)
0
10000
20000
30000
40000
50000
p= 0.2
a
re
a
 u
n
d
e
r 
c
u
rv
e
 (
A
U
C
)
      9 wpi (63dpi)
0
10000
20000
30000
40000
a
re
a
 u
n
d
e
r 
c
u
rv
e
 (
A
U
C
)
0
10000
20000
30000
40000
  11 wpi (77dpi)
*p<0.05
a
re
a
 u
n
d
e
r 
c
u
rv
e
 (
A
U
C
)
        15wpi (105 dpi)
0
10000
20000
30000
40000
a
re
a
 u
n
d
e
r 
c
u
rv
e
 (
A
U
C
)
0
10000
20000
30000
40000  *P<0.05
8wpi (56dpi)
a
re
a
 u
n
d
e
r 
c
u
rv
e
 (
A
U
C
)
0
5000
10000
15000
20000
25000 p= 0.055
11 wpi (77dpi)
a
re
a
 u
n
d
e
r 
c
u
rv
e
 (
A
U
C
)
         16 wpi (112dpi)
0
10000
20000
30000
40000 p= 0.1
a
re
a
 u
n
d
e
r 
c
u
rv
e
 (
A
U
C
)
0
10000
20000
30000
40000
   9 wpi (63dpi)
a
re
a
 u
n
d
e
r 
c
u
rv
e
 (
A
U
C
)
7-8 weeks 
(49-56 dpi)
9-10 weeks
(63-70 dpi)
11 weeks
(77 dpi)
15-16 weeks
(105-112 dpi)
Balb/C HF Balb/C HF Ls 
0
10000
20000
30000
40000 *p<0.05
11wpi (77dpi)
a
re
a
 u
n
d
e
r 
c
u
rv
e
 (
A
U
C
)
13-14 weeks
(91-98 dpi)
        13wpi (91dpi)
0
10000
20000
30000
40000
A
U
C
 (
ar
ea
 u
n
d
er
 c
u
rv
e)
0
10000
20000
30000
40000
            14wpi (98dpi)
ar
ea
 u
n
d
er
 c
u
rv
e 
(A
U
C
)
 Results 
45 
 
PCR array data showed that L.s. infection tended to promote insulin signaling in DIO 
mice as shown by a stronger expression of Irs1 (p=0.18), a gene that codes for the 
synthesizing of the IRS-1 protein that plays a role in the insulin signaling cascade 
[167]. Carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1) was 
significantly upregulated in L.s.-infected DIO mice (p<0.05), suggesting an improved 
insulin signaling and glucose tolerance [168,169] (Fig. 12 and Table S1). In lipid 
metabolism, L.s. infection may promote ß-oxidation in mitochondria in EAT of DIO 
mice as a trend for an upregulated Ppara (p=0.19) expression was observed, while TG 
production and adipogenesis were suppressed as represented by a downregulated 
glycerol-3-phosphate dehydrogenase-1 (Gpd1) (p<0.05) expression and a trend to a 
suppressed Pparg (p=0.09) as well as CCAAT/enhancer binding protein alpha (Cebpa) 
(p=0.18) gene expression (Fig. 12 and Table S1). This suppression of adipogenesis was 
not only shown in L.s.-infected DIO mice, but also in L.s.-Infected mice which received 
a chow diet (Fig. 12B and Table S2). In addition, vascular endothelial growth factor 
(Vegf) and nitric oxide synthase 3 (Nos3) were weaker expressed in EAT of L.s.-
infected DIO mice (p<0.05 and p=0.19), indicating that L.s. infection suppressed 
angiogenesis, restricted adipose tissue expansion, or reduced hypoxia in EAT, which 
results in a reduced angiogenesis (Fig. 12 and Table S1). 
In line with previous FACS analysis of SVF from EAT which showed an increased 
recruitment of eosinophils, L.s. infection was accompanied with an increased 
leukocyte migration as highlighted by the upregulation of adhesion molecule genes 
including Selectin-L (Sell) (p<0.05) and intercellular adhesion molecule-1 (Icam1) 
(p=0.17). This was further supported by a stronger trend in Ccl5 expression (p=0.15), a 
chemoattractant chemokine that is involved in the migration of T cells and 
eosinophils from blood plasma into the tissue (Fig. 12).  
In addition, L.s. infection in DIO mice led to an increased expression of Cd28 (p=0.12), 
a co-stimulatory molecule expressed on T cells as well as Ctla4 (p=0.14), a gene which 
codes for a protein receptor that induces tolerance [170] (Fig. 12 and Table S1). 
Although Foxp3 as marker of regulatory T cells was not upregulated in EAT of L.s.-
infected DIO mice, L.s.-infected animals that were fed with a chow diet had a 
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tendency of Foxp3 upregulation (p=0.09) in EAT (Fig. 12B and Table S1). Furthermore, 
expression of phosphoinositide-3-kinase, catalytic, delta polypeptide (Pik3cd), a 
regulator of B1 function [171], tended to be increased in L.s.-infected DIO mice 
(p=0.18) (Fig. 12 and Table S1). This supports our previous FACS analyses of EAT that 
demonstrated an increased frequency of B1 cells in L.s. infection (Fig. 8-D). Moreover, 
PCR array data analyses indicates an increased anti-inflammatory response which was 
shown by a trend to a higher expression of Il-10 (p=0.19) (Fig. 12 and Table S1). 
Accordingly, the inflammatory adipokine Resistin tended to be suppressed by L.s. 
infection (p=0.12). However, L.s. infection also tended to increase the inflammatory 
gene Ifng (p= 0.21) (Fig. 12 and Table S1). 
In the fed state, a tendency of increased phosphoenolpyruvate carboxykinase 1 (Pck1) 
(p=0.07) expression in adipocytes of L.s.-infected mice may indicate an effort to re-
ester FFA to TG, which could restrict FFA release from adipocytes into the blood 
circulation [172]. In line with this, glucose-6-phosphate dehydrogenase (G6pd) 
expression tended to be suppressed by L.s. infection (p=0.06). This could increase 
insulin sensitivity, as overexpression of G6pd was previously shown to elevate FFA 
release and insulin resistance [173].  
Although the majority of the results obtained from gene expression analysis in EAT of 
L.s.-infected DIO mice was in line with glucose tolerance improvement, the expression 
of a few genes were negatively correlated with glucose tolerance improvement. This 
included the observed downregulation of dual specificity phosphatase-4 (Dusp4) 
(p<0.05) and the increased expression of the inflammatory cytokine Ifng (p=0.23), 
which was associated with HF diet-induced inflammation in two previous studies 
[174,175] 
Most of these differences did not reach statistical significance due to the low sample 
size. Nevertheless, they indicate that L.s. infection may reduce inflammation in EAT, 
increased insulin signaling and ß-oxidation, while reducing adipogenesis in DIO mice 
(Fig. 13). Similarly, gene analysis in L.s.-infected mice with chow diet showed an up-
regulation of genes-related to anti-inflammatory immune responses and a down-
regulation of genes related to adipogenesis (Fig. 12B and Table S1).  
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Figure 12. L.s. infection induces an anti-inflammatory immune response and reduces adipogenesis. 
RT2 Profiler PCR array analysis of gene expression in EAT of (A) L.s.-infected (n=3) compared to 
uninfected BALB/c mice (n=3) maintained on high fat (HF) diet, and (B) L.s.-infected (n=3) compared 
to uninfected BALB/c mice (n=3) on a chow diet (NF). Red arrows indicate genes with up-regulated 
expression and green arrows represent down-regulated gene expression. Data illustrates genes that 
have fold change values > 1.3, p<0.2. Genes that are significantly different (p<0.05) are highlighted in 
bold. 
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Figure 13. Analysis of gene expression in EAT of L.s.-infected (n=3) and uninfected BALB/c mice 
(n=3) maintained on high fat diet compared to uninfected BALB/c mice on high fat diet (n=3) based 
on genes function. Right diagram represents genes with up-regulated (red) expression, left diagram 
represents down-regulated (green) genes expression in L.s.-infected DIO mice compared to 
uninfected DIO mice controls. Data illustrate genes that have fold change values > 1.5, p<0.2 
compared to BALB/c controls on a high fat diet. 
 
3.7 L.s. antigen administration reduces adipogenesis in vitro 
To confirm the finding of the qPCR array that suggested a suppressed adipogenesis in 
L.s.-infected mice, LsAg treatment of the 3T3-L1 pre-adipocyte cell line culture was 
performed to test the effect of helminth antigens on adipogenesis in vitro (Fig. 14A). 
After 8 days of treatment, LsAg-treated cells showed less mature adipocytes compared 
to untreated cells (Fig. 14B). Accordingly, absorbance of Oil Red O staining of lipid 
droplets (p<0.05; Fig. 14C) and TG levels (p>0.05; Fig. 14D) were lower in LsAg-treated 
than untreated cells. These results indicate that LsAg treatment suppresses adipocyte 
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maturation. Viability tests with MTT assay further demonstrated no difference 
amongst cell viability of PBS-treated control, LsAg-treated and troglitazone-treated 
cells, indicating that the reduced adipogenesis by LsAg treatment was not caused by a 
cell toxic effect.  
 
Figure 14. LsAg treatment suppresses adipogenesis in the 3T3-L1 adipose cell line. (A) LsAg 
treatment regimen during 3T3-L1 differentiation. 9 days post confluence, cells were stained with Oil 
Red O to identify mature adipocytes. (B) Representative pictures taken from Oil Red O stained cells 
that were either treated only with differentiation medium, cells treated with differentiation medium 
+ LsAg, and cells treated with differentiation medium + troglitazone as positive control. (C) 
Absorbance of Oil Red O color intensity, (D) triglyceride levels of 3T3-L1 cell culture supernatant. (E) 
Cell viability after 2 days of LsAg and troglitazone treatment. Statistical significance was determined 
using Kruskal-Wallis followed by Dunn’s multiple comparisons test. Data are expressed as means + 
SEM. *p<0.05. 
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3.8 Daily LsAg administration for 2 weeks improves glucose tolerance in DIO mice 
Since our previous finding showed an improvement of glucose tolerance in L.s.-
infected DIO mice, we tested whether administration of crude extracts of L.s. (LsAg) 
and other helminth-derived products including ES-62, CPI, and ALT improve glucose 
tolerance in DIO mice. Daily i.p. injections of 2µg LsAg, ES-62, CPI, and ALT were 
administered to C57BL/6 mice started at 7 weeks on HF diet for 2 weeks. Glucose 
tolerance test was performed following the last day of administration.  
Given that the earlier experiment in DIO mice with L.s. infection as well as 3T3-L1 cell 
line culture with LsAg treatment suggested an inhibition of adipogenesis, it was 
further investigated whether LsAg administration inhibits adipogenesis in vivo. For 
this purpose, whole body weight and fat tissue mass of mice were analyzed. Body 
weight developments among all groups showed no difference during the high fat diet, 
although CPI-treated animals had a tendency for a lower body weight compared to 
the other groups (Fig. 15A, B). Perirenal and EAT adipose tissue weights were not 
different among the groups (Fig. 15C, D). These findings revealed that two weeks of 
treatment with helminth-derived products of DIO mice did not induce weight loss (Fig 
15A-E).  
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Figure 15. Two weeks of helminth-derived product administration does not induce weight loss in 
DIO mice. A) Body weight development during HF diet of mice that were treated daily for two weeks 
with PBS, LsAg, CPI, ES-62 and ALT started at 7 weeks on HF diet. B) Body weight after 9 weeks on HF 
diet. Comparison of C) perirenal adipose tissue, D) epididymal adipose tissue, E) total adipose tissue 
weight. Statistical significance was determined using Kruskal-Wallis followed by Dunn’s multiple 
comparisons test. Data are expressed as means + SEM.  
 
While body weight among the groups were not different, blood glucose tolerance of L.s.-
infected DIO mice was significantly improved compared to PBS-treated DIO controls and ES-
62-treated DIO mice (Fig. 16A, B). In addition, CPI and ALT administration tended to improve 
glucose tolerance compared to PBS-treated controls, although this difference did not reach 
statistical significance. Despite the improvement of glucose tolerance by administration of 
LsAg, CPI and ALT, insulin tolerance of all treatment groups were not improved (Fig 16C, D).      
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Figure 16. Two weeks of LsAg administration improves glucose tolerance in DIO mice. A) Blood 
glucose levels over time following i.p. glucose challenge in LsAg, CPI, ES-62, and ALT-treated mice 
and PBS-treated controls that received a HF diet for 9 weeks. B) Area under the curve obtained from 
the glucose tolerance test. C) Blood glucose levels over time following i.p. insulin challenge in LsAg-
treated mice and PBS-treated controls that received a HF diet for 10 weeks. D) Area under the curve 
obtained from the insulin tolerance test. Statistical significance was determined using Kruskal-Wallis 
followed by Dunn’s multiple comparisons test. Data are expressed as means + SEM. *p<0.05. 
 
3.9 Daily LsAg administration for 2 weeks increases the frequency of eosinophils and 
AAM in EAT 
In line with the cellular composition of EAT in L.s.-infected mice, LsAg-treated mice 
demonstrated an increased frequency of eosinophils (Fig 17A), but no reduction of 
macrophage frequencies in SVF of EAT. However, although CPI and ALT 
administration improved glucose tolerance to some degree in DIO mice, they did not 
increase the frequency of eosinophils, indicating that glucose tolerance improvement 
in CPI and ALT administration are independent on eosinophils. Conversely, although 
ES-62 administration significantly increased the frequency of eosinophils (Fig. 17A) it 
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did not improve glucose tolerance in DIO mice. The frequency of neutrophils in EAT of 
DIO mice was not reduced by LsAg, CPI and ALT administration (Fig. 17B). 
Nevertheless, in ES-62-treated DIO mice, the frequency of neutrophils was 
significantly reduced (Fig.17B). CD4 frequencies of EAT in LsAg-treated DIO mice was 
significantly higher than in CPI-treated animals and tended to be increased compared 
to PBS treated DIO mice (Fig. 17C). The frequency of macrophages within EAT during 
HF diet among the groups were not different (Fig. 17D), suggesting that helminth 
antigen did not restrict macrophage infiltration during HF diet feeding. However, the 
frequency of CAM was reduced in all of the helminth antigen administrations, 
reaching statistical significance in the LsAg-treated DIO mice (Fig. 17E). In line with the 
increased frequency of eosinophils, AAM frequency was also increased in EAT of DIO 
mice that received LsAg and ES-62 administration compared to controls, indicating 
that eosinophils have a role in AAM polarization by LsAg and ES-62 administration. 
Although the eosinophil frequency was not increased in CPI-treated DIO mice, the 
frequency of AAM in that group was also increased compared to PBS control (Fig. 
17F). The cell compositions in EAT indicate that each helminth-derived product (LsAg, 
CPI, and ALT) improve glucose tolerance via different mechanisms, and increases of 
eosinophils and AAM do not always a line with improved glucose tolerance as shown 
in ES-62-treated DIO mice. 
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Figure 17. Impact of LsAg, CPI, ES-62, and ALT administration (n=6 per group) on the cellular 
composition within EAT during HF diet. Frequency of (A) eosinophils, (B) neutrophils, (C) CD4 T cells, 
(D) macrophages, (E) macrophages expressing CD11c (CAM), (F) macrophages expressing RELMα 
(AAM) within the SVF of EAT of DIO mice. Statistical significance was determined using Kruskal-Wallis 
followed by Dunn’s multiple comparisons test. Data are expressed as means + SEM. *p<0.05, 
**p<0.01. 
 
Consistent with the increased frequency of AAM in EAT of LsAg-treated DIO mice, Arginase 1 
gene expression tended to be upregulated after 2 weeks of LsAg administration (Fig 18A) 
and parallel to the improvement of glucose tolerance, Pparg and Glut4 expression tended to 
be increased in EAT of LsAg-treated DIO mice (Fig 18B,C). These initial findings suggest that 
LsAg administration improves glucose tolerance in DIO mice through induction of insulin 
signaling. While insulin signaling was improved by LsAg administration, anti-inflammatory 
Il10 gene expression was not upregulated in DIO mice that were treated with all of the 
different helminth-derived products (Fig. 18D). Conversely, Resistin expression, an adipokine 
which is proposed to cause insulin resistance [176] was upregulated in all of the helminth-
derived product administrations compared to PBS treated DIO control mice (Fig. 18E).  
PBS LsAg CPI ES62 ALT
0
5
10
15
20
**
**
e
o
s
in
o
p
h
il
s
 [
%
]
PBS LsAg CPI ES62 ALT
0
1
2
3
**
n
e
u
tr
o
p
h
il
s
 [
%
]
PBS LsAg CPI ES62 ALT
0.0
0.5
1.0
1.5
*
C
D
4
 [
%
]
PBS LsAg CPI ES62 ALT
0
10
20
30
40
50
m
a
c
ro
p
h
a
g
e
s
 [
%
]
A B C
D
PBS LsAg CPI ES62 ALT
0
10
20
30
*
C
A
M
 [
%
 m
a
c
ro
p
h
a
g
e
s
]
PBS LsAg CPI ES62 ALT
0
20
40
60
80
*
*
A
A
M
 [
%
 m
a
c
ro
p
h
a
g
e
s
]
E F
 Results 
55 
 
A recent study identified transcriptional regulator interacting with the PHD-bromodomain 2 
/ SERTA domain-containing protein 2 (Trip-Br2/Sertad2), a protein that modulates fat 
storage through simultaneous regulation of lipolysis, thermogenesis and oxidative 
metabolism. The absence of Trip-Br2/Sertad2 has been shown to protect mice from obesity-
related insulin resistance, and was associated with increased thermogenesis and energy 
expenditure [177]. Interestingly, ALT and ES-62 administrations significantly suppressed 
expression of Trip-Br2 in DIO mice, while LsAg administration had no effect (Fig. 18F), 
suggesting that both ALT and ES-62 may have an impact in energy expenditure. 
 
Figure 18. Relative gene expression of (A) Arginase-1, (B) Pparg, (C) Glut4, (D) Il10, (E) Resistin , and 
(F) Trip-Br2/Sertad2 within EAT of helminth antigen or PBS-treated DIO mice. Statistical significance 
was determined using Kruskal-Wallis test followed by Dunn’s multiple comparisons test. Data are 
expressed as means + SEM. *p<0.05, **p<0.01. 
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the improved glucose tolerance in DIO mice and whether prolonged treatment with 
LsAg provides a better effect two repeat experiments were performed. A prolonged 
LsAg administration with three administrations per week for a total of 4 weeks failed 
to improve glucose tolerance in DIO mice compared to PBS controls and was 
associated with an increased body weight in the LsAg treated mice (Fig. 19A-C). In 
addition, glucose tolerance was also not improved when tested 2 weeks after the last 
LsAg injection (Fig. 19D-F). These findings suggest that a continuously administration 
of LsAg should be given to keep the beneficial effect on glucose tolerance. 
 
Figure 19. Discontinuous LsAg administration failed to improve glucose tolerance in DIO mice. (A) 
Blood glucose levels over time during a glucose tolerance test and (B) area under the curve of the 
glucose tolerance test. (C) Body weight of mice on HF diet after 4 weeks of injections with LsAg and 
PBS (3x per week). (D) Blood glucose levels over time during a glucose tolerance test and (E) area 
under the curve of the glucose tolerance test. (F) Body weight of mice on HF diet 2 weeks after 14 
days of daily LsAg or PBS injection. Statistical significance was determined between HF diet groups 
using Mann-Whitney-U-test. Data are expressed as means +SEM *p < 0.05. 
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Interestingly, a repeated round of daily i.p. LsAg injections of mice shown in Fig. 19D-F 
for another two weeks improved the glucose tolerance when tested four days after 
the last injection (Fig. 20A,B). These findings further confirm that continuous LsAg 
administration was required to improve glucose tolerance in DIO mice. Therefore, 
further experiments should test whether continuous release of LsAg by osmotic pumps 
provides a better protective effect against insulin resistance. 
 
Figure 20. Repeated LsAg administration in DIO mice does not affect adipose tissue weight. (A) 
Blood glucose levels over time during a glucose tolerance test and (B) area under the curve of the 
glucose tolerance test from animals used for Fig. 19D-F, after two additional weeks of daily LsAg or 
PBS treatments. (C) Body weight development during HF and chow diet, (D) epididymal adipose 
tissue weight, (E) subcutaneous adipose tissue weight, as well as (F) brown adipose tissue weight. 
Statistical significance for (C-F) were determined using Kruskal-Wallis followed by Dunn’s multiple 
comparisons test. For (A) and (B), statistical significance were determined between HF diet groups 
using Mann-Whitney-U-test. Data are expressed as means +SEM *p < 0.05; **p < 0.01. 
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3.11 Repeated LsAg administration does not restrict adipogenesis  
To confirm our findings in the previous experiment regarding the impact of LsAg 
administration on adipogenesis in vivo, the body weight and adipose tissue mass of 
DIO mice was analyzed after 2 weeks of LsAg administration. As shown in Fig. 20, there 
were no significant differences in body weight as well as epididymal, subcutaneous 
and brown adipose tissue weight between PBS- and LsAg-treated groups. This 
indicates and confirms our previous experiment that two weeks of LsAg administration 
are not sufficient to reduce adipogenesis in DIO mice (Fig. 20D-F). 
It has been described that hypertrophy of adipocytes is correlated with inflammation-
induced insulin resistance. Nevertheless, although LsAg administration improved 
glucose tolerance, adipocytes in both EAT and ScAT which were analyzed in LsAg- and 
PBS-treated DIO mice did not display a difference in diameter size (Fig. 21A-H), 
indicating that two weeks of LsAg administration does not suppress adipogenesis and 
fatty acid storage in adipocytes in vivo when administered after the development of 
glucose intolerance. 
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Figure 21. Two weeks of LsAg administration does impact adipocytes size. Structure of EAT of 
control mice on chow diet (A), PBS-treated DIO mice (B) and LsAg-treated DIO mice (C) as well as (D) 
epididymal adipocytes size. Structure of subcutaneous adipose tissue of control mice on chow diet 
(E), PBS-treated DIO mice (F) and LsAg-treated DIO mice (G) as well as (H) subcutaneous adipocyte 
size. For Fig. A-C the bar represents 200µm, for Fig. E-G the bar represent 100µm. Statistical 
significance was determined using Kruskal-Wallis followed by Dunn’s multiple comparisons test. 
Data are expressed as means + SEM. 
 
Analyses of EAT revealed that the total number of leucocytes was increased in DIO mice and 
was not altered by two weeks of LsAg treatment (Fig. 22A). In line with our previous findings 
in L.s.-infected DIO mice and the first LsAg-treatment experiment in DIO mice, analysis of 
the cell composition of EAT by flow cytometry confirmed a significant higher frequency of 
eosinophils in LsAg-treated DIO mice compared to PBS-treated DIO controls (Fig. 22B). As 
expected, LsAg-treated DIO mice further had a higher frequency of RELMα+ macrophages, 
but less CD11c+ CAM compared to DIO control mice (Fig. 22C-E), suggesting that LsAg 
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administration improves glucose tolerance by increasing eosinophil and AAM frequencies in 
adipose tissue. Furthermore, CD4 T cell frequencies in LsAg-treated DIO mice were 
significantly higher compared with PBS-treated DIO controls (Fig. 22F). CD4 T cells were 
further assessed for FoxP3 positivity. Surprisingly, frequencies of CD4+FoxP3+ regulatory T-
cells were higher in PBS-treated DIO controls compared to LsAg-treated mice (Fig. 22G). 
However, absolute numbers of CD4+FoxP3+ regulatory T-cells within EAT tended to be 
higher in LsAg-treated DIO mice (p>0.05; Fig. 22H), indicating that LsAg administration 
increases the recruitment of regulatory T-cells into the EAT of DIO mice. 
 
Figure 22. Repeated LsAg administration increases the frequency of eosinophils and alternatively 
activated macrophages within EAT. (A) Total number of leucocytes in EAT of LsAg- and PBS-treated 
DIO mice and PBS-treated chow diet controls. Frequency of (B) eosinophils, (C) macrophages, (D) 
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macrophages expressing CD11c (CAM), (E) macrophages expressing RELMα (AAM). (F) Frequency of 
CD4 T cells, (G) frequency of FoxP3+ CD4 T cells and (G) total number of CD4+ FoxP3+ T cells within 
EAT of LsAg- or PBS -treated DIO mice and chow diet controls. Statistical significance was determined 
using Kruskal-Wallis followed by Dunn’s multiple comparisons test. Data are expressed as means + 
SEM. *p<0.05, **p<0.01.  
 
3.12 LsAg administration induces an anti-inflammatory immune response and promotes 
insulin signaling 
To identify the impact of LsAg administration in DIO mice, particularly in mRNA levels, 
expression analysis of 84 genes in EAT of LsAg-treated mice (n=10) and PBS-treated 
controls (n=8) that received a HF diet, as well as corresponding chow diet controls 
were performed using a PCR Array (SABioscience). Gene expression data that had a 
fold change >1.3 are presented in Fig. 23 and Table S3.  
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Figure 23. Volcano plot representing gene expression data from EAT of DIO mice which were 
treated with LsAg (n=10) compared to PBS-treated controls (n=8). The x axis represents the fold 
change (given in log2), whereas the y-axis represents the p-value (given in log10). The blue line 
represents p = 0.05 with points above the line having p < 0.05. Red circles have a fold change of 
more than 1.3, the green circles have a fold change of less than -1.3.  
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3.12.1 LsAg administration upregulates genes related to insulin signaling 
In line with our previous finding that revealed an improvement of glucose tolerance 
in LsAg- treated mice, DIO mice that received i.p. LsAg injections had a significantly 
higher expression of genes-related to insulin signaling such as solute carrier family 2 
(facilitated glucose transporter), member 4 (Slc2a4) or Glut4, phosphodiesterase 3B 
(Pde3b), Phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (Pik3r1) and 
hexokinase-2 (Hk2) compared to DIO mice that received PBS (p<0.05). Furthermore, 
there were tendencies of a higher expression of Irs1 (p=0.11) and Irs2 (p=0.14) in 
LsAg-treated DIO mice. These indicate that LsAg administration increased insulin 
signaling in EAT of DIO mice. Subsequently, LsAg administration had a tendency for 
an increased expression of adiponectin (adipoq) (p=0.18), an adiponectin coding 
gene, and increased expression of adiponectin receptor-2 (adipor2, p<0.05) in EAT of 
DIO mice. Therefore, these may further support the improvement of insulin signaling 
in DIO mice that obtained LsAg treatment.  
3.12.2 2 weeks of daily LsAg administration increases the expression of genes related to 
fatty acid uptake and energy anabolism 
In accordance with the improved insulin signaling, the cell metabolism in LsAg-
treated DIO mice exerted an anabolic state including lipogenesis and glycogenesis. 
Accordingly, upregulation of sterol regulatory element binding transcription factor 1 
(Srebf1) (p<0.05), fatty acid synthase (Fasn) (p<0.01), acetyl-coenzyme A carboxylase 
alpha (Acaca) (p<0.05) and Pparg (p<0.05), indicate an increased lipogenesis in 
adipocytes of DIO mice that received LsAg. Moreover, the tests revealed that 
expression of genes related to fatty acid uptake including fatty acid binding protein 4 
(Fabp4) and Lpl (both p<0.05), as well as very low density lipoprotein receptor (Vldr) 
(p=0.06) were increased in LsAg-treated DIO mice. Furthermore, array analysis 
indicated that the storage of excessive energy is not only generated as lipid 
formation, but also as glycogen as shown by glycogen synthase (Gys) upregulation in 
LsAg-treated DIO mice (p<0.05).  
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3.12.3 Inflammasome activation-induced apoptosis in EAT of LsAg-treated DIO mice is 
suppressed 
In addition to the upregulation of genes related to insulin signaling and fatty acid 
uptake, we also found that expression of genes related to inflammatory immune 
responses tended to be downregulated in LsAg-treated mice. Tumor necrosis factor 
receptor superfamily member 1B (Tnfrsf1b) expression that encodes the membrane 
receptor for TNFα, tended to be suppressed in LsAg-treated DIO mice (p=0.17). 
Moreover, LsAg administration slightly suppressed inflammasome activation-induced 
apoptosis as were shown by downregulation of NLR family, pyrin domain containing 
3 (Nlrp3) (p=0.17), PYD and CARD domain containing (Pycard) (p=0.09), and caspase-
1 (Casp1) (p=0.11).  
In line with the downregulation of genes involved in inflammatory responses and 
apoptosis, LsAg administration reduced macrophage recruitment into EAT as was 
highlighted by a downregulation of epidermal growth factor module-containing 
mucin-like receptor 1 (Emr1) (F4/80) (p=0.056).  
3.13 LsAg administration increases CD4 T cell recruitment in EAT and induces Th2 
immune responses 
Infiltration of CD4 T cells was increased in LsAg-treated mice as was shown by a 
stronger expression of CD3 antigen, epsilon polypeptide (Cd3e) (p<0.05) and 
confirmed our previous results on CD4+ T cells from flow cytometry. Furthermore, a 
trend to a higher expression of chemokine (C-C motif) receptor type 4 (Ccr4) (p=0.10) 
in EAT of LsAg-treated DIO mice indicates an increased Th2 infiltration in EAT since 
Ccr4 is highly expressed on the surface of Th2 cells, suggesting that LsAg 
administration induces a Th2 polarization.  
Interestingly, DIO mice that received LsAg treatment showed a suppressed expression 
of genes related to atherothrombotic formation such as serine (or cysteine) peptidase 
inhibitor, clade E, member 1 (Serpine1) (p=0.06) [29], suggesting that LsAg 
administration may provide a beneficial impact on cardiovascular disease prevention. 
Although most of gene expression analysis revealed an upregulation of genes related 
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to the improvement of insulin signaling, Ifng expression in LsAg-treated DIO mice was 
increased (p<0.05). In addition, array analysis also showed an upregulation of 
pyruvate dehydrogenase kinase, isoenzyme 2 (Pdk2), which was previously associated 
with T2D [179]. With exception for these two genes, the findings of the array analysis 
indicate that LsAg administration suppresses apoptosis-induced inflammasome 
activation, promotes insulin signaling in EAT and increases glucose and fatty acid 
uptake into white adipocytes.  
3.14 LsAg administration increases AAM polarization, regulatory T cells and type 2 
immune responses within EAT 
In order to obtain a better understanding regarding the underlying mechanism of 
improved glucose tolerance upon LsAg administration, several additional gene 
expression analyses were performed from EAT. In line with the previous FACS analysis 
of EAT that highlighted increased frequencies of F4/80+ RELMα+ AAM upon LsAg 
administration, the expression of arginase-1 (p<0.01) (Fig. 24A), a gene expressed in 
AAM, was significantly upregulated in EAT of LsAg-treated DIO mice. This confirms 
that LsAg administration increases AAM polarization in EAT of DIO mice.  
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Figure 24. Daily LsAg administration for 2 weeks increases the expression of genes associated with 
type 2 immune responses in EAT of DIO mice. Gene expression of Arg1 (A), Foxp3 (B), Il10, and (C) 
Gata3 (D). Gene expression is given as fold changes after normalization to β-actin. Statistical 
significance was determined using Mann-Whitney-U-test. Data are expressed as means + SEM. *p < 
0.05, **p <0.01. 
 
As shown by our earlier data, FACS analysis of EAT revealed an increased CD4 
frequency in LsAg-treated DIO mice. However it remained unclear whether LsAg 
increased CD4 regulatory T cell numbers in EAT since the frequency of CD4+FoxP3+ 
cells in LsAg-treated DIO mice was lower compared to PBS-treated controls although 
the absolute number showed the opposite. To confirm whether LsAg treatment 
increased regulatory T cells in EAT of DIO mice, Foxp3 gene expression analysis was 
performed. Foxp3 gene expression was significantly increased in EAT of LsAg-treated 
DIO mice compared to PBS-treated DIO controls (p<0.01, Fig. 24B), suggesting that 
HF PBS HF LsAg
0
1
2
3 **
Foxp3
F
o
ld
 c
h
a
n
g
e
A BArg1
HF PBS HF LsAg
0
5
10
15
20
**
F
o
ld
 c
h
a
n
g
e
C
HF PBS HF LsAg
0.0
0.5
1.0
1.5
2.0
Il10
p = 0.2301
F
o
ld
 c
h
a
n
g
e
D Gata3
HF PBS HF LsAg
0
1
2
3
4 **
F
o
ld
 c
h
a
n
g
e
 Results 
67 
 
LsAg administration increased total numbers of regulatory T cells in EAT of DIO mice. 
Since regulatory T cells play an important role in maintaining glucose homeostasis in 
lean mice [64], this may contribute to the protective effect of LsAg treatment. 
However, analysis of Il10 gene expression revealed that its expression by LsAg 
administration was not statistical significant (p=0.23, Fig. 24C). 
Furthermore, in line with the tendency of an increased Th2 induction as was indicated 
by an increased expression of Ccr4, a significantly higher expression of the Th2 
transcription factor GATA binding protein 3 (Gata3) [180] was observed (p<0.01, Fig. 
24D). This result highlights that LsAg administration induces type 2 immune 
responses. 
Collectively, data from PCR arrays and additional gene expression analyses suggest 
that LsAg administration induced type 2 immune responses, increased AAM and 
regulatory T cells as well as promoted insulin signaling in EAT, thus increasing glucose 
and FFA uptake into white adipocytes.   
3.15 LsAg administration may induce browning of fat in EAT 
Since LsAg administration induced an increase of eosinophils and AAM within EAT, 
further investigation was conducted to investigate whether LsAg treatment induced 
browning of EAT and ScAT of DIO mice. The PCR array analysis from EAT of DIO mice 
included genes that were related to browning of adipose tissue such as Ucp1, 
Ppargc1a and Pparg. Those PCR array results showed that Pparg, a gene which was 
reported to play a role in browning of adipose tissue [181] was upregulated in LsAg-
treated DIO mice (p<0.05), whereas the increased expression of Ppargc1a (Pgc1a) in 
LsAg treated animals did not reach statistical significance (fold change = 1.93, 
p=0.156, Fig. 23 and Table S3) and no differences were observed for the expression of 
Ucp1 in EAT of DIO mice that received LsAg or PBS administration (fold change =1.01, 
p=0.95). Since beige cells are more prominent in ScAT, gene expression analyses of 
Pparg and Ucp1 were performed from ScAT. However, both Pparg (p=0.089) and 
Ucp1 (p=0.331) expression was not significantly increased by LsAg treatment (Fig. 
25A, B).  
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Figure 25. Gene expression levels in subcutaneous adipose tissue (ScAT) of DIO mice after 2 weeks 
of daily LsAg or PBS ip injection. Relative mRNA levels of (A) Pparg, and (B) Ucp1 in ScAT after 
normalization to ß-actin. At least 5 samples per group were used for analysis. Statistical significance 
was determined using Mann-Whitney-U-test. Data are expressed as means + SEM. 
  
Given that browning of adipose tissue is enhanced during cold, cold exposure at 5°C was 
performed after 2 weeks of daily LsAg or PBS injection in DIO mice to investigate the impact 
of LsAg administration on browning of adipose tissue under cold induction. Development of 
hypothermia was reduced in LsAg-treated DIO mice compared to PBS-treated controls, and 
reaching statistical significance within the first 2 hours of cold exposure (Fig. 26A). 
Accordingly, Ucp1 expression was significantly increased in EAT of LsAg-treated mice after 
4h of cold exposure (Fig. 26B). Furthermore, an increased expression of Gata3, Il4 and Il5 
(Fig. 26C-E) indicated the induction of type 2 immune responses in LsAg-treated DIO mice 
after 2 weeks of LsAg treatment. Moreover, as expected, Arg1 expression was significantly 
upregulated in DIO that received LsAg treatment. These findings indicate that LsAg 
administrations induced browning of white adipose tissue under cold exposure via the 
induction of type 2 associated cytokines and AAM.  
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Figure 26. Two weeks of daily LsAg administration promotes thermogenesis and beiging of EAT of 
DIO mice under cold exposure. A) Body temperature kinetics during a cold exposure at 5oC of mice 
that received daily injections of LsAg or PBS for 14 days and were fed on a HF diet for a total of 4 
weeks. Gene expression of (B) Ucp1, (C) Gata3, (D) Il5, (E) Il4, (F) Arg1 in the EAT of those mice. Gene 
expression is given as fold change after normalization to β-actin. Statistical significance was 
determined using Mann-Whitney-U-test. Data are expressed as means + SEM. *p < 0.05, **p <0.01. 
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4. Discussion 
In this thesis, it was tested whether L.s. infection and filarial antigen administration have 
a beneficial impact on obesity-induced insulin resistance and the underlying mechanism 
was investigated. Numerous studies reported that chronic inflammation in obesity-
induced insulin resistance is associated with increased frequencies of CAM and a 
reduction of AAM in visceral adipose tissue due to excessive expansion of adipose tissue 
[45,164,182]. On the other hand, filarial infection and its antigen induce regulatory 
immune response in their hosts via the induction of Tregs, AAM, anti-inflammatory 
cytokines, and induce a type 2 immune response that counter regulates type 1 immune 
responses. Several beneficial impacts and possible mechanisms of filarial infection and 
its antigen to counter insulin resistance due to chronic inflammation in visceral adipose 
tissue were investigated in this thesis.  
4.1 High fat diet induces glucose intolerance in obese mice 
As a storage organ, fat tissue has an almost unlimited capacity to store excessive 
energy. During HF diet, lipid droplet formation in the adipocytes continuously 
increases to store excessive energy and leads to lipid accumulation and adipocyte 
enlargement called hypertrophy [18]. As seen in mice that received long term HF diet, 
fat tissue in the whole body expands, especially in the subcutaneous and visceral 
adipose tissue, and increased body weight occurs. Gradual adipocyte hypertrophy 
and tissue expansion lead to a deficiency of oxygenation of cells due to an imbalance 
between the increase of oxygen demand and supply by blood innervations 
[20,183,184]. Overtime, adipocytes suffer from hypoxia and undergo oxidative stress 
which can initiate inflammatory cytokine production and apoptosis [19,20]. Released 
cytokines along with apoptotic cells induce infiltration of macrophages into the 
adipose tissue, augment inflammation by additional cytokine production and 
eventually alter cell composition in visceral adipose tissue. The chronic inflammation 
caused by CAM and adipocyte stress inhibit the insulin signaling cascade in the cells of 
the body ubiquitously [25,41,185]. Consequently, glucose in the circulation cannot be 
taken up into the cells, which leads to glucose intolerance upon glucose challenge. 
Accordingly, experiments of this thesis demonstrate that both body weight and 
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adipose tissue mass of mice that received a HF diet for at least 8 weeks were 
increased compared to mice with a normal chow diet. This was accompanied by 
larger diameters of adipocytes in both EAT and ScAT. Further analysis carried out by 
flowcytometry revealed an increased frequency of CAM within EAT of mice on HF 
diet, suggesting an increased recruitment of macrophages. Ultimately, glucose 
intolerance occurred in DIO mice as a consequence of inhibited insulin signaling due 
to chronic inflammation.  
4.1.1 Changes of the cellular composition by L.s. infection and LsAg counter-regulate 
chronic inflammation in DIO mice 
As presented in our study, both L.s. infection and helminth-derived products improve 
glucose tolerance. This beneficial effect was accompanied with an increased 
frequency of eosinophils, AAM, and a decreased frequency of B cells. Since AAM in 
adipose tissue maintain insulin sensitivity in lean mice [41,45,185], induction of AAM 
by helminth-induced type 2 immune responses could dampen obesity-induced 
insulin resistance.  
L.s. is well known to induce systemic type 2 immune responses in mice [166,186] and 
results from this thesis demonstrate that L.s. infection and LsAg administration also 
increased the frequency of eosinophils and F4/80+ RELMα+ AAM within EAT of DIO 
mice. Those changes correlated with an improvement of glucose tolerance in both 
L.s.-infected and LsAg-treated DIO mice. This finding is therefore, in accordance with 
Wu et al. that showed an improvement of glucose tolerance in N. brasiliensis-
infected DIO mice which was accompanied by increased numbers of eosinophils and 
AAM in EAT [44]. AAM are generated in vitro by exposure to IL-4 and IL-13 via the 
STAT6 signaling pathway [57,63]. In contrast to CAM, AAM express low levels of pro-
inflammatory cytokines and generate high levels of anti-inflammatory cytokines like 
IL-10 [45]. Moreover, increased arginase production in AAM counters iNOS activity 
by several mechanisms, including competition for the substrate arginine that is 
required for NO production [61]. Therefore, increased AAM frequencies in EAT of 
obese mice are believed to suppress inflammatory responses thus promoting glucose 
tolerance. This is in line with findings from this thesis, as improved glucose tolerance 
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was accompanied by an upregulated Il10 expression in EAT of L.s.-infected DIO mice 
as well as an upregulated arginase1 expression in EAT of DIO mice that were treated 
with LsAg. 
4.1.1.1 Eosinophils are indispensable for glucose tolerance improvement by L.s. infection 
Wu et al. revealed that eosinophil-derived IL-4 was essential to maintain AAM in 
adipose tissue [44]. Eosinophil-produced IL-4 was also shown to have an important 
role for nutrient metabolism and insulin sensitivity via STAT6 signaling. Absence of 
STAT6, which is important for AAM polarization, impaired insulin signaling, while 
reactivation of STAT6 signaling via IL-4 improves insulin sensitivity by inhibiting the 
PPARα-induced nutrient catabolism and reduces adipose tissue inflammation [53].  
In addition, IL-4 administration reduces adiposity in DIO mice by increasing beige 
fat mass and thermogenic capacity thus increasing energy expenditure [54]. IL-4 
further increased AKT phosphorylation in liver and muscle thus improving insulin 
sensitivity [53,187]. Therefore, as a major source of IL-4, helminth-induced 
eosinophils may be indispensable for improvement of glucose tolerance in obese 
mice. In accordance, L.s.-infection failed to improve glucose tolerance in 
eosinophil-deficient dblGATA mice in this thesis. In the absence of eosinophils, L.s. 
infection did not lead to an increased frequency of AAM in EAT, suggesting that 
eosinophils are indeed required to improve glucose tolerance by sustaining AAM 
presence in adipose tissue of obese mice.  
4.1.1.2 Glucose tolerance improvement by L.s. infection was associated with a reduction 
of B cell accumulation and an expanded B1-cells subset 
The past decade revealed that chronic inflammation in adipose tissue does not 
only involve innate immunity, but also adaptive immunity. It was previously shown 
that total B cell numbers peak after 3–4 weeks after initiation of HF diet in visceral 
adipose tissue [46,71] and induces a class switch to IgG in B cells of the visceral 
adipose tissue, thus enhancing pro-inflammatory IgG2c production which 
promotes macrophage-mediated inflammation via a Fc-mediated process [46]. B 
cells isolated from adipose tissue also induced CD4+ and CD8+ T cell IFNγ and 
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CXCL8 production, whereas IL-10 release was decreased, which could further 
trigger the inflammatory process [188]. While increased B cell numbers promote 
insulin resistance in obese mice, mice lacking B cells are protected from insulin 
resistance and depletion of B cells improves insulin sensitivity in DIO mice [46]. 
Interestingly, the glucose tolerance improvement in our experiments was also 
accompanied with a lower number of B cells in SVF of EAT in L.s.-infected DIO mice 
compared to DIO controls. In line with the reduction of total B cell numbers in EAT, 
IgG2a levels were also reduced, which is comparable to a reduction of IgG2c in 
C57BL/6 mice [189]. This suggests that reduced B cell numbers in EAT of L.s.-
infected mice diminish HF diet–induced inflammation. Furthermore, the B1 cell 
subset was significantly increased in L.s.-infected compared to uninfected DIO 
controls. Since B1 cells are a source of IL-10 [190,191], the expanded B1-cell subset 
may contribute to of the protective effect seen in L.s.-infected mice. Future studies 
should therefore assess whether B cells from L.s.-infected DIO mice are less 
pathogenic compared to B cells from DIO controls.  
4.1.2 Glucose tolerance improvement by helminth infection could be elucidated by 
suppression of adipogenesis 
As obesity is the major risk factor to develop insulin resistance, numerous studies 
were conducted to develop strategies to overcome obesity thus preventing the 
onset of metabolic syndrome, including diabetes. Interestingly, an epidemiological 
study in humans and experimental studies in animals reported a correlation between 
helminth infection and parameters related to obesity inhibition. Thus, people in a 
rural area in China with a history of schistosomiasis had a lower BMI (body mass 
index) compared to endemic controls that never suffered from schistosomiasis [98]. 
Indication that helminth infection may indeed inhibit obesity comes from animal 
studies with N. brasiliensis. Wu et al. (2011) found that N. brasiliensis-infected mice 
had a lower perigonadal (epididymal) adipose tissue weight [44]. Similarly, Yang et 
al. demonstrated a lower body weight development and less visceral fat pad mass in 
N. brasiliensis-infected mice that were fed on a HF diet compared to uninfected mice 
[192]. N. brasiliensis infection also induced weight loss in DIO mice after 14 weeks of 
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HF diet [192]. In their study, intestinal helminth infection impaired the glucose 
absorption of the intestine and led to a reduced body weight. As additional 
mechanism, N. brasiliensis-infection induced a type 2 immune response, which led to 
an activation of STAT6 signaling and reduced lipogenesis and thus adipose tissue 
mass [192]. However, to what level altered food intake or pathology contributed to 
these effects are not clear. Interestingly, suppression of adipogenesis was not only 
present in gastrointestinal helminth infections like N. brasiliensis, but was also 
induced by infection with L.s., which resides in the pleural cavity. Our multiple genes 
expression analyses of EAT in DIO BALB/c mice showed a downregulation of genes 
related with adipogenesis such as Pparg, Gpd1 and Cebpa in EAT of L.s.-infected 
mice, indicating that glucose tolerance improvement in L.s. infection might also be 
elucidated by suppression of adipogenesis although the body weight between those 
two groups was not significantly different. Consistent with the downregulation of 
several genes related with adipogenesis in L.s.-infected mice, in vitro experiments 
with the 3T3-L1 pre-adipocyte cell culture demonstrated that LsAg-treated cells have 
less mature adipocytes compared to untreated cells. The mechanism by which LsAg 
suppresses adipocyte maturation is not fully understood, but was not due to a toxic 
effect, as cell viability was not altered. One possible explanation is the induction of 
RELMα, since the addition of RELMα was reported to down-regulate adipocyte 
differentiation markers, including Pparg, Cebpa, adipocyte Protein-2 (aP2), Adipoq, 
and Glycerol-3-phosphate dehydrogenase (Gpdh) [193]. Nevertheless, daily LsAg 
administration for 2 weeks did not suppress adipogenesis in vivo although glucose 
tolerance in LsAg-treated DIO mice was improved, suggesting that suppression of 
adipogenesis is not the major protective effect.  
4.1.3 The beneficial effect of L.s. infection on glucose tolerance improvement is 
dependent on the time point of infection 
Data from several time points of L.s. infection indicated that at 7-8 weeks and 11 
weeks post infection, glucose tolerance of L.s.-infected DIO were consistently 
improved, whereas 9-10 and more than 11 weeks post infection did not show such a 
protective effect. It is likely that the development of L.s. in its host is causing those 
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differences on the impact of glucose tolerance. Although adult worms have been 
reported to induce Th2 immune responses [186,194,195], microfilariae were 
reported to provoke Th1 immune responses [195]. Isolated spleen cells from 
microfilariae-injected mice produced high levels of IFNγ upon Brugia malayi antigen 
stimulation [195]. In L.s.-infected WT mice, microfilaremia starts around 8 weeks 
post infection and reaches its peak around 75 days post infection [166], and steadily 
decreases afterwards. Thus, those time points of peak microfilaremia correlated with 
an impaired protective effect on glucose tolerance. Stimulation of isolated pleural 
lavage cells from 60 dpi L.s.-infected WT mice with LsAg revealed high levels of IFNγ 
[166] and injection of L.s. microfilariae in naïve mice were previously shown to 
induce IFNγ, MIG and IL-12 [196]. Similarly, PCR array results from LsAg treated and 
L.s. infected DIO mice also indicated an increased IFNγ expression in EAT. Since IFNγ 
was reported to impair insulin signaling via activation of the JAK-STAT1 pathway 
[175], this may explain why L.s. infection did not improve glucose tolerance after 9 
weeks of infection. Accordingly, treatment with filarial antigen preparations 
obtained from prepatent filariae may further improve its efficacy to treat insulin 
resistance.  
4.2 The impacts of helminth-derived product administration on DIO mice 
Data from this thesis demonstrate that glucose tolerance improvement in DIO mice 
was not only achieved by infections with living worms, but was also accomplished in 
obese mice after two weeks of daily LsAg, CPI as well as ALT administration, but not 
by treatment with ES-62. Similar to L.s. infection, LsAg, ES-62, and CPI administration 
increased the frequency of AAM in EAT. However, although ES-62 administration 
induced increased frequencies of eosinophils and AAM, it did not improve glucose 
tolerance in DIO mice. Nevertheless, since it mimicked the impact of LsAg in 
restoring the cell composition in EAT, further investigation should be performed with 
different dosage regimens to test their efficacy on glucose tolerance induction.  
Although CPI administration did not increase the frequency of eosinophils, it 
improved glucose tolerance. Interestingly, EAT of CPI-treated mice contained 
increased frequencies of AAM in the absence of an increased number of eosinophils, 
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suggesting that glucose tolerance improvement by CPI administration may be 
produced by a different mechanism. Such a possible mechanism is the suppression 
of adiposity in CPI-treated mice since CPI-treated mice that received HF diet had a 
lower body weight and adipose tissue mass compared to the other groups.  
Unlike ES-62, CPI, and LsAg-treated animals, ALT-treated DIO mice did neither show 
an increased frequency of eosinophils nor AAM within EAT. Nevertheless, ALT-
treated DIO mice had a reduced frequency of macrophages and CAM within EAT, 
indicating that its administration restricted macrophage infiltration during HF diet.  
4.2.1 Glucose tolerance improvement by both L.s. infection and LsAg administration is 
not mediated by increased IL-10 responses  
Filarial infection and LsAg administration did not only induce AAM and eosinophils, 
but also regulatory T cells that are another hallmark of helminth infections [197]. 
Two weeks of LsAg administration increased the number of CD4+ FoxP3+ regulatory 
T cells in SVF of EAT, which was confirmed by upregulated Foxp3 expression in EAT. 
Furthermore, Foxp3 expression was increased in EAT of L.s.-infected DIO mice and 
L.s.-infected lean mice. As reported by Feuerer et al., along with AAM, regulatory T 
cells are a potential source of IL-10, an anti-inflammatory cytokine that was shown 
to improve insulin sensitivity [64]. Although potential IL-10 producing cells like AAM 
and CD4+ Foxp3+ were increased in our experiment, both IL-10 mRNA levels and Il-
10 protein concentrations were not increased in EAT and serum of DIO mice treated 
with LsAg, suggesting that IL-10 is not essential for the improvement of glucose 
tolerance in this context.  
4.2.2 LsAg administration upregulates Pparg expression in EAT of DIO mice 
Although gene expression of adipogenesis markers were downregulated in L.s.-
infected mice and in vitro LsAg-treated 3T3-L1 cells were less mature, we found no 
differences in body weight development, adipose tissue weights, and adipocytes size 
in DIO mice that received two weeks of LsAg administration. In contrast to the gene 
expression analysis in EAT of L.s.-infected mice, PPARγ, an adipogenesis marker was 
upregulated in EAT of LsAg-treated DIO mice, indicating that LsAg administration 
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improved glucose tolerance without inhibiting adipogenesis. A similar paradoxical 
effect of PPARγ in promoting adipogenesis and improving glucose homeostasis and 
insulin sensitivity was reported by numerous studies [198–201]. Several studies 
reported that transgenic mice with an increased PPARγ activity are protected from 
obesity-associated insulin resistance [202], whereas mice lacking PPARγ in fat, 
muscle, or liver are predisposed to develop insulin resistance [200,201,203,204]. 
Thiazolidinedione (TZDs), a high-affinity agonist for PPARγ, was also found to be an 
effective treatment for T2D as it directly reduces systemic insulin resistance of 
peripheral tissues [199,205]. In addition, PPARγ has been reported to mediate anti-
inflammatory effects through inhibition of NFκB, activator protein-1 (AP1), and STAT 
transcription factors [206]. Taken together, although PPARγ promotes adipocyte 
differentiation and adipogenesis, PPARγ enhances insulin sensitivity and suppresses 
inflammation thus improving glucose tolerance in DIO mice. In this context, the 
upregulation of PPARγ in DIO mice that received LsAg administration is plausible to 
improve glucose tolerance.  
4.2.3 Glucose tolerance improvement is associated with LsAg-induced type 2 immune 
responses  
As has been shown in this thesis, a strong induction of type 2 immune response 
including upregulation of Gata3, Il5 and IL4 expression in EAT of DIO mice which 
received LsAg administration was observed. In line with this, Ccr4 expression, a Th2 
marker tended to be increased after 2 weeks of LsAg administration. These confirm 
our earlier findings in FACS analysis that revealed an increase of type 2 associated 
cells including eosinophils and AAM in EAT of L.s.-infected and LsAg-treated DIO 
mice.  
Th2-associated cytokines like IL-5 and IL-4 can be also provided by type 2 innate 
lymphoid cells (ILC2s), a new innate lymphoid subset, which also expresses GATA3 
[207,208]. Upregulation of Il5 and Il4 in LsAg-treated DIO mice may therefore 
indicate an increase of either Th2 cells or ILC2s in EAT of DIO mice. Type 2 immune 
responses during LsAg administration may improve insulin sensitivity in DIO mice 
since overexpression of IL-5 has been reported to play a key role in maintaining 
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eosinophils and promoting AAM activation in visceral adipose tissue and to promote 
glucose tolerance in mice which received HF diet, whereas the absence of IL-5 or 
eosinophils impaired glucose tolerance in DIO mice [209]. This beneficial effect was 
predicted due to the increase of oxidative metabolism and suppression of 
inflammation, which will reduce adiposity and promote insulin sensitivity [53].  
4.2.4 Increase of energy expenditure by LsAg administration may improve glucose 
tolerance in DIO mice 
The biology of brown adipose tissue has received growing attention over the last few 
years to counter obesity and its related diseases. In contrast to white adipose tissue 
which functions as storage of lipid excess, the main function of brown adipose tissue 
is the dissipation of chemical energy in the form of heat, thus increasing energy 
expenditure [155]. Surprisingly, a number of studies have identified another type of 
adipocytes that expresses high levels of mitochondrial uncoupling protein-1 (UCP-1) 
which is induced by “browning” of white adipose tissue by chronic cold exposure and 
β-adrenergic stimulation [210,211]. These “brown-like” cells are also called “beige” 
or “brite” cells and are distributed within the white adipose tissue [212,213]. 
Absence of beige cells in adipo- PRD1-BF-1-RIZ1 homologous domain containing 
protein-16 (PRDM16) KO mice led to an increased susceptibility to obesity and 
metabolic dysfunctions including hepatic insulin resistance [214]. Since beige cells 
possess the capacity to burn energy from fat by producing heat, browning of white 
adipose tissue may be a novel target to increase energy expenditure, thus combating 
obesity and T2D.  
Interestingly, recent studies demonstrated that browning of white adipose tissue 
correlated with AAM and eosinophils [54,55]. Upon eosinophil-derived IL-4 release, 
adipose tissue macrophages develop an AAM polarization [44], release 
catecholamines, activate β-adrenergic signaling and drive thermogenesis [54,56]. In 
accordance, LsAg administration in DIO mice increased eosinophils, AAM, and 
induced type 2 immune responses. Upon cold exposure, LsAg-treated DIO mice 
developed better body temperature tolerance. Increased expression of Ucp1 in 
these mice further indicates that LsAg administration promotes beiging of white 
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adipose tissue by providing high number of eosinophils and AAM, thereby inducing 
thermogenesis and increasing energy expenditure in DIO mice. Since PPARγ agonist 
was also reported to induce browning of white adipose tissue via stabilization of 
PRDM16 protein [181], the upregulation of Pparg expression in EAT of LsAg-treated 
DIO mice also supports an increased energy expenditure in those mice. In addition to 
reduced adiposity, lipid ß-oxidation for thermogenesis could enhance utilization of 
fatty acids, thereby increasing FFA uptake into the cells, thus reducing FFA levels in 
the circulation. This may attenuate lipotoxicity-induced insulin resistance. 
4.2.5 Array analysis revealed an improved insulin signaling and fatty acid uptake in EAT 
of LsAg-treated DIO mice 
Although LsAg administration did not suppress adiposity, PCR array analysis of EAT 
from LsAg-treated DIO mice indicated a suppression of inflammatory responses as 
was shown by a slight downregulation of Tnfrsf1b expression. Since TNFα signaling 
induces insulin resistance, lower expression of Tnfrsf1b may help to maintain insulin 
sensitivity in LsAg treated mice. Insulin sensitivity improvement upon LsAg 
administration in obese mice further correlated with a significantly higher expression 
of Pik3r, which encodes the p50α, p55α, and p85α regulatory subunits of 
phosphatidylinositol 3 kinases (PI3Ks), and has a key role for insulin signaling by 
activating AKT [215,216]. Activated AKT in turn phosphorylates PDE3B, which further 
promotes expression of Slac2a4 (Glut4) and promotes glucose uptake into the cells 
[217]. In addition, increased expression of the Adipor2 in EAT of LsAg-treated DIO 
mice can enhance insulin signaling to promote GLUT4 translocation by binding with 
adiponectin [218].  
Increased expression of genes correlated to insulin signaling in LsAg-treated DIO 
mice as highlighted above may therefore maintain insulin’s function in cell 
metabolism. As an anabolic hormone, the binding of insulin with its receptor in 
induces in the fed state glucose and fatty acid uptake to store excessive energy 
intake in the form of glycogen and lipid. Consequently, lipogenesis and glycogenesis 
were more stimulated in LsAg-treated compared to PBS-treated DIO mice as was 
shown by a higher expression of Srebf1, Fasn, and Acaca which contribute to fatty 
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acid synthesis as well as Gys, which plays a role in glycogenesis. In addition to the 
enhanced glucose uptake, insulin signaling increased fatty acid uptake into the cells 
as indicated by upregulated expression of Fabp4 and Lpl as well as vldlr. Accordingly, 
both body weight and adipocytes size in EAT of LsAg-treated DIO were not different 
compared to PBS-treated DIO, suggesting that there is no suppression of lipogenesis 
upon LsAg administration. These findings suggest that LsAg administration improves 
insulin sensitivity without suppression of adiposity. 
Given that the inflammasome activation by FFA leads to lipotoxicity and results in 
apoptosis of adipocytes which triggers additional inflammatory responses [219], 
increased FFA uptake by adipocytes upon LsAg administration may restrict 
inflammasome-induced apoptosis by reducing FFA in the circulation. A tendency of 
lower expression of Nlrp3, Pycard as well as Casp1 upon LsAg administration 
supports this hypothesis. Therefore, LsAg administration may avoid adipocyte stress 
and apoptosis which may ultimately result in less inflammatory cytokine production 
and macrophage recruitment. Accordingly, a lower macrophage infiltration was 
shown by FACS analysis and lower expression of Emr1 (F4/80) by PCR array. 
Suppressive inflammatory immune responses in turn maintain insulin sensitivity in 
EAT. Although some genes related to inflammation were suppressed upon LsAg 
treatment, we also found that Ifng expression was significantly increased in adipose 
tissue of LsAg-treated mice. This increased Ifng expression could be due to 
endosymbiotic Wolbachia bacteria that are found in most human pathogenic filariae 
as well as L.s. [114,220] and increased IFNγ levels were previously associated with 
the release of the microfilarial stage [195,196]. Elevated Ifng expression within EAT 
of LsAg-treated mice may attenuate the beneficial effect of LsAg administration. 
Therefore, further studies regarding the effect of LsAg from Wolbachia-depleted 
worms should be conducted to reduced pro-inflammatory responses caused by 
Wolbachia. 
In general, we found an association between the improvement of glucose tolerance 
in both L.s.-infected DIO mice and LsAg-treated DIO mice with an increased number 
of eosinophils and AAM which was accompanied by increased type 2 immune 
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responses and expression of genes linked to insulin signaling. Continuity of LsAg 
administration was needed to ameliorate glucose tolerance in DIO mice as long as HF 
diet continued. 
4.3 Conclusion 
In conclusion, this thesis demonstrates that both L.s. infection and LsAg treatment of 
DIO mice improves glucose tolerance and leads to an increased number of 
eosinophils, AAM and CD4+ Foxp3+ regulatory T cells within the EAT. Eosinophils are 
required to mediate the protective effect in L.s.-infected DIO mice and additional 
protective mechanisms may include the suppression of adipogenesis. In contrast, 
LsAg administration improves glucose tolerance without suppression of adipogenesis. 
Gene expression analysis highlighted that LsAg administration promotes insulin 
signaling in EAT of DIO mice. This exerts uptake of glucose via GLUT4 and fatty acids 
via the LPL and VLDL receptor from the circulation into the cells. Insulin signaling and 
uptake of fatty acid in turn reduced TG levels in the blood thus preventing 
lipotoxicity-induced insulin resistance in other tissues. 
Type 2 immune responses, along with increased frequencies of eosinophils and AAM 
in EAT of DIO mice indicated a browning of white adipose tissue upon cold exposure, 
thus promoting energy expenditure. In addition, increased energy expenditure may 
increase the utilization of FFA to reduce lipotoxicity-induced insulin resistance. 
Therefore, LsAg administration is a promising therapy against obesity and its related 
diseases.  These findings suggest that filariae induce several protective mechanisms 
that should be pursued in order to develop new strategies to ameliorate insulin 
resistance in human T2D. 
4.4 Outlook 
• Elevated Ifng expression during LsAg administration could be due to lipoproteins 
from Wolbachia, which could reduce the beneficial impact of LsAg. Further studies 
should be conducted to investigate whether Wolbachia-depleted LsAg further 
improves insulin sensitivity in HF diet-induced insulin resistant mice.  
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• Since our experiments demonstrated that the beneficial impact of LsAg 
administration is no longer present several days after the treatment is stopped, a 
modified therapy consistent of a long term treatment and continuous slow release 
of LsAg should be tried, e.g. via the implantation of osmotic pumps. 
• Future experiments should include the analysis of mice in metabolic cages to 
obtain a better picture of the metabolic changes. 
• Studies regarding the impact of LsAg administration on liver and muscle tissue are 
required to obtain better understanding how LsAg affects energy metabolism. 
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5. Appendix 
 
5.1 Table S1. Comparison of diabetes-related gene expression between L.s.-infected DIO 
(n=3) and uninfected DIO mice (n=3). The table lists fold changes for genes that 
exhibit at least a 1.5-fold change when EAT of L.s.-infected DIO mice is compared to 
EAT of uninfected DIO mice. Red fold changes indicate upregulated genes compared 
to controls, while blue fold changes highlight downregulated genes compared to 
controls. Statistical significant differences (p < 0.05) are shown in red color.  
 
Gene Symbol Fold Change t-Test 
  HF L.s / HF Uninf. p value 
Ace 1.839 0.286823 
Ccl5 4.4144 0.14551 
Cd28 2.9259 0.116235 
Ceacam1 3.1143 0.046104 
Ctla4 21.0472 0.136601 
Dpp4 2.0594 0.278991 
Enpp1 2.0452 0.091382 
Foxp3 1.7 0.458718 
Glp1r 5.0358 0.270648 
Icam1 2.0264 0.168345 
Ifng 117.9656 0.214471 
Il10 3.4396 0.190844 
Il12b 2.4947 0.247776 
Inppl1 14.5091 0.165306 
Ins1 1.5286 0.43024 
Irs1 1.6345 0.183127 
Pck1 1.5716 0.070911 
Pfkfb3 1.797 0.630151 
Pik3cd 1.7681 0.177571 
Ppara 1.5972 0.196131 
Rab4a 2.0642 0.355155 
Sell 3.4795 0.013394 
Hnf1b 31.245 0.372507 
Tnf 1.9349 0.225582 
Adra1a -1.7026 0.124435 
Ccr2 -1.6258 0.600397 
Cebpa -1.9378 0.184165 
Dusp4 -2.9508 0.042055 
G6pc -1.6561 0.332967 
G6pd2 -2.8768 0.067003 
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Gpd1 -2.3968 0.04047 
Hnf4a -1.9112 0.407527 
Igfbp5 -3.0549 0.086491 
Il6 -5.9564 0.464393 
Nos3 -2.0015 0.190899 
Pparg -1.7956 0.093176 
Retn -3.3507 0.128151 
Serpine1 -3.6497 0.269378 
Stxbp1 -7.5568 0.682317 
Vamp3 -1.9786 0.151319 
Vegfa -1.8503 0.034739 
 
5.2 Table S2. Comparison of diabetes-related gene expression between L.s.-infected 
mice (n=3) and uninfected mice (n=3) with normal chow diet. The table lists fold 
changes for genes that exhibit at least a 1.5-fold change when EAT of L.s.-infected and 
uninfected mice are compared. Red fold changes indicate upregulated genes 
compared to controls, while blue fold changes highlight downregulated genes 
compared to controls. Statistical significant differences (p < 0.05) are shown in red 
color 
 
Genes 
Fold Change t-Test 
NF L.s. / NF Uninf. p value 
Ccl5 4.9895 0.33484 
Foxp3 10.3548 0.097135 
Gcg 2.3223 0.131485 
Hmox1 12.314 0.506217 
Icam1 2.1768 0.295093 
Ifng 8.9728 0.27438 
Il10 2.559 0.342021 
Il6 2.8723 0.395458 
Retn 3.361 0.659846 
Sell 2.1124 0.378368 
Srebf1 2.879 0.818365 
Tnf 3.3378 0.290015 
Tnfrsf1a 16.2859 0.740888 
Ace -3.0478 0.054201 
Acly -1.9244 0.810571 
Adrb3 -1.8291 0.507211 
Agt -1.6485 0.970347 
Akt2 -1.622 0.529489 
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Aqp2 -1.8675 0.290219 
Cebpa -1.6523 0.718491 
Dpp4 -3.148 0.07046 
Foxc2 -1.6108 0.861539 
G6pc -4.9398 0.338341 
G6pd2 -2.8968 0.278797 
Gcgr -1.7264 0.586311 
Gpd1 -1.9786 0.977361 
Gsk3b -1.8418 0.25342 
Hnf4a -2.5867 0.189191 
Igfbp5 -3.3275 0.063823 
Irs1 -1.6371 0.342047 
Nos3 -8.2885 0.886111 
Nrf1 -9.0701 0.078861 
Pck1 -2.2106 0.431709 
Pik3r1 -2.0201 0.500968 
Ppara -2.1255 0.476968 
Pparg -2.2415 0.30708 
Ppargc1a -1.6108 0.583102 
Pygl -1.8461 0.358524 
Serpine1 -3.3045 0.321022 
Sod2 -1.6071 0.218434 
Trib3 -1.6034 0.370869 
Vamp2 -1.7627 0.178702 
Vapa -1.5169 0.260782 
 
5.3 Table S3. Comparison of diabetes-related gene expression between LsAg-treated 
(n=10) and PBS-treated (n=8) mice receiving a high fat diet. Displayed are fold-
changes and p-values of genes expressed in EAT derived from LsAg-treated DIO mice 
in comparison to PBS-treated DIO controls (cut off 1.3 fold change). Upregulated 
genes are indicated in red, downregulated genes are presented in blue. P-values < 
0.05 are presented in red.  
 
Gene Symbol Fold Regulation p-value 
Srebf1 1.7578 0.004987 
Fasn 1.9762 0.012098 
Pdk2 1.8898 0.018928 
Lpl 1.3601 0.019036 
Pde3b 2.0122 0.021991 
Pik3r1 1.6676 0.022137 
Acaca 1.9585 0.026172 
Adipor2 1.5754 0.027524 
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Ifng 1.4993 0.033234 
Hk2 1.4661 0.034874 
Gys1 1.6865 0.036739 
Slc2a4 2.2199 0.037317 
Pparg 1.4492 0.038214 
Cd3e 2.0234 0.043157 
Fabp4 1.627 0.04822 
Chuk 1.6055 0.056951 
Vldlr 1.3599 0.061409 
Rps6kb1 1.3412 0.065711 
Retn 2.371 0.072863 
Lipe 1.68 0.078575 
Ccr4 2.7193 0.103747 
Irs1 1.4835 0.116958 
Scd1 2.6624 0.13008 
Pck1 2.7401 0.136777 
Irs2 1.3837 0.14121 
Lep 1.4241 0.149471 
Ppargc1a 1.9275 0.156765 
Il18r1 1.5867 0.163892 
Rbp4 2.1641 0.168106 
Adipoq 1.9242 0.183023 
Ppara 1.3482 0.191082 
Acacb 1.6558 0.201308 
Ccr6 2.8333 0.232769 
Pdx1 1.5559 0.307193 
Il23r 1.6194 0.490008 
Mapk9 1.3777 0.903007 
Emr1 -2.482 0.05594 
Serpine1 -1.9053 0.059855 
Pycard -1.6754 0.09398 
Casp1 -1.4184 0.113289 
Tnfrsf1b -1.6609 0.168709 
Nlrp3 -1.6737 0.176981 
Cxcr4 -1.4974 0.183075 
Tnf -1.5294 0.237718 
Crlf2 -1.34 0.26139 
Ccr5 -1.6716 0.421126 
Il6 -1.5268 0.580275 
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5.4 Table S4. The list of primer sequences used in experiment 
 
Gene Forward ('5---3') Reverse ('5---3') 
mouse Arginase 1 CCTATGTGTCATTTGGGTGGA CAGGAGAAAGGACACAGGTTG 
mouse Foxp3 TCTTGCCAAGCTGGAAGACT GGGGTTCAAGGAAGAAGAGG 
mouse IL-10 GGTTGCCAAGCCTTATCGGA ACCTGCTCCACTGCCTTGCT 
mouse IL-5 AGCACAGTGGTGAAAGAGACCTT TCCAATGCATAGCTGGTGATT 
mouse IL-4 ACAGGAGAAGGGACGCCAT GAAGCCCTACAGACGAGCTCA 
mouse Gata3 GTCATCCCTGAGCCACATCT AGGGCTCTGCCTCTCTAACC 
mouse Ucp1 CTGCCAGGACAGTACCCAAG TCAGCTGTTCAAAGCACACA 
mouse β-Actin AGAGGGAAATCGTGCGTGAC CAATAGTGATGACCTGGCGGT 
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List of abbreviations 
 
AAM alternatively activated macrophages  
Acaca Acetyl-Coenzyme A carboxylase alpha 
Adipoq adiponectin 
Adipor Adiponectin receptor 
ALT abundant larval transcript 
AP1 activator protein 1 
aP2 adipocyte Protein-2 
APC antigen–presenting cells  
arg1 Arginase1 
AUC area under the curve 
BSA bovine serum albumin 
B2M beta-2-microglobulin 
Cebpa CCAAT/enhancer binding protein alpha 
CAM classically activated macrophages 
cAMP cyclic Adenosine Monophosphate 
Ca calsium 
Casp1  Caspase1 
CCL chemokine (C-C motif) ligand  
Ccr4 Chemokine (C-C motif) receptor 4 
Cd cluster of differentiation 
Cd3e CD3 antigen, epsilon polypeptide 
cDNA complementary DNA 
Ceacam1 Carcinoembryonic antigen-related cell adhesion molecule 1 
CPI cysteine proteinase inhibitor 
Ctla4 cytotoxic T-lymphocyte-associated protein 4 
Cxcr4 C–X–C chemokine receptor type 4 
DEC diethyl carbamazine 
DIO diet-induced obese  
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic Acid  
dNTP Deoxynucleotide 
dpi days post infection 
DSS Dextran sulfate sodium 
Dusp4 dual specificity phosphatase 4  
EAT Epididymal adipose tissue  
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay  
Emr1 epidermal growth factor module-containing mucin-like receptor 1  
Enpp1 Ectonucleotide pyrophosphatase/phosphodiesterase 1 
EPO eosinophil peroxidase  
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ER endoplasmic reticulum  
ES Excretory secretory 
Fabp4 Fatty acid binding protein 4 
FACS Fluorescence-Activated Cell Sorter 
Fasn Fatty acid synthase 
Fc fragment crystallizable  
FFA Free fatty acid 
Fig. Figure 
FITC Fluorescein isothiocyanate 
Foxp3 forkhead–winged-helix transcription factor-3 
FSC Forward scatter 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
Gata3 GATA binding protein 3 
GITR glucocorticoid-induced TNF receptor 
Glut4 Glucose transporter type 4 
Gpd1 glycerol-3-phosphate dehydrogenase-1 
Gpdh Glycerol-3-phosphate dehydrogenase 
GTT Glucose tolerance test  
Gys  Glycogen synthase 1 
G6pd Glucose-6-phosphate dehydrogenase 
Hb hemoglobin 
HEPES N-2-Hydroxyethylpiperazine-N'-2-Ethanesulfonic Acid 
HF high fat 
Hk2 Hexokinase-2 
HOMAIR homeostatic model assessment for insulin resistance   
HRP horseradish peroxidase 
i.p intra peritoneal 
Icam1 intercellular adhesion molecule 1 
IDF International Diabetes Federation  
Ifng Interferon gamma 
IKKβ IҡBα kinase β 
IL-4Rα IL-4 receptor-alpha 
ILC2 type 2 innate lymphoid cells 
iNOS inducible nitric oxide synthase 
Irs1 Insulin receptor substrate 1 
Irs2 Insulin receptor substrate 2 
iTreg inducible Treg 
ITT Insulin tolerance test 
L Larvae 
L.s Litomosoides sigmodontis 
Lpl   Lipoprotein lipase 
LsAg Litomosoides sigmodontis antigen 
M molar 
MBP major basic protein  
MCP  monocyte chemotactic protein  
mf microfilariae 
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Mg magnesium 
MHC major histocompatibility complex 
mM mili molar 
MS Multiple sclerosis 
µl micro liter 
µm micro meter 
Nlrp3 NLR family, pyrin domain containing 3 
nm nano meter 
NO nitric oxide  
NOD non obese diabetic  
Nos3 nitric oxide synthase 3 
Nrf1 nuclear factor (erythroid-derived 2)-like 1 
O. bacoti Ornithonyssus bacoti  
OD optical density  
PAI Plasminogen activator Inhibitor 
PBS Phosphat Buffer Saline 
Pck1  phosphoenolpyruvate carboxykinase 1 
PCR polymerase chain reaction 
Pde3b phosphodiesterase 3B 
Pdk2 Pyruvate dehydrogenase kinase, isoenzyme 2 
PE phycoerythrin 
PGC-1β peroxisome proliferator-activated receptor gamma coactivator 1β  
PI3Ks phosphatidylinositol 3 kinases  
Pik3cd phosphoinositide-3-kinase, catalytic, delta polypeptide 
Pik3r1  Phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 
alpha) 
Ppara Peroxisome Proliferator-Activated Receptor Alpha 
Pparg Peroxisome proliferator activated receptor gamma 
PRDM16 PRD1-BF-1-RIZ1 homologous domain containing protein-16 
Pycard  PYD and CARD domain containing 
qPCR quantitative real-time polymerase chain reaction 
RELMα Resistin-like molecule α 
RNA ribonucleic acid 
ROS reactive oxygen species  
rpm rotations per minute 
RQI RNA quality indicator  
RT room temperature 
ScAT Subcutaneous adipose tissue 
SEA soluble egg antigen 
Sell  Selectin L 
Serpine1 Serine (or cysteine) peptidase inhibitor, clade E, member 1 
Slc2a4 Solute carrier family 2 (facilitated glucose transporter), member 4 
Srebf1 Sterol regulatory element binding transcription factor 1 
SSC Side scatter 
ß-islet  beta islet 
STAT6 signal transducer and activator of transcription 6  
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STH Soil-transmitted helminth 
SVF stromal vascular fraction  
SWA soluble worm antigen  
T1D type 1 diabetes  
T2D type 2 diabetes  
TG Triglyceride 
TGF-ß transforming growth factor beta 
Tlr Toll-like receptor 
TMB tetramethylbenzidine 
Tnfrsf1b tumor necrosis factor receptor superfamily member 1B 
Uninf. uninfected 
Vamp2 vesicle-associated membrane protein 2 
VAT Visceral adipose tissue 
Vegf  Vascular endothelial growth factor 
VLDL very low density lipoproteins  
Vldlr Very low density lipoprotein receptor 
w/v weight per volume ratio 
wpi  weeks post infection 
WT wild type  
# number/count 
˚C degree celcius 
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